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ABSTRACT OF THE DISSERTATION
POLY-TOBACCO USE AMONG YOUTH AND ADULTS IN THE UNITED STATES
by
Olatokunbo Osibogun
Florida International University, 2019
Miami, Florida
Professor Wasim Maziak, Major Professor
This dissertation 1) described prevalence and correlates of poly-tobacco use among US
youth and young adults; 2) addressed positive and negative transitions of e-cigarettes among US
youth and adults and 3) examined the 2-year transition of dual e-cigarette/cigarette use among US
adults in relation to nicotine dependence (ND) symptoms, interest in quitting, and cardiovascular
disease (CVD) factors. Data from 2013-2016 of the Population Assessment of Tobacco and
Health Study were used.
In the first study, 3.6% of youth (12-17years) and 18.3% of young adults (18-34years)
were current poly-tobacco users between 2013-2014. Common poly-tobacco products
combination was cigarettes and e-cigarettes for youth and young adults. Among youth, heavy
drinking was associated with higher odds of poly-tobacco use. Factors associated with higher
odds of poly-tobacco use among young adults included males, younger adults (18-24years), those
with lower levels of educational attainment, residing in the South, heavy drinking, and marijuana
use.
In the second study, between 2013-2016, e-cigarette use increased only in youth. Young
e-cigarette users were more likely to be never cigarette smokers compared to older users. Among
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youth e-cigarette users at each wave, the proportion of never cigarette smokers rose from 24.1%
in Wave 1 to 42.6% in Wave 3 (p=0.0001 for trends). Among adult e-cigarette dual users in
Wave 1, 8.8% transitioned to no tobacco use at Wave 3, 6.2% to mono e-cigarette use, while 85%
either relapsed to cigarettes (53.5%) or continued dual use (31.5%).
In the final study, among 1,870 adult dual tobacco users from Wave 1, 25·8% (95% CI
23·5-28·3) remained dual users 2 years later, 11·9% (95% CI 10·5-13·5) reported no tobacco use
(cessation transition), 7·0% (95% CI 5·5-8·7) reported e-cigarette mono use (harm reduction
transition), and 55·3% (95% CI 52·6-58·0) reported cigarette mono use (relapse transition). In the
adjusted regression analysis, ND severity was associated with lower odds of cessation (OR 0·36;
95% CI 0·15-0·88) and harm reduction (OR 0·18; 95% CI 0·04-0·82) transitions. Interest in
quitting and CVD factors were not associated with cessation or harm reduction.
Collectively, our study findings emphasize the need for stricter tobacco regulatory
policies to prevent another tobacco epidemic.
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Introduction
Poly-tobacco use (concurrent use of two or more tobacco products) is a common public
health problem (McMillen et al., 2012; Lee et al., 2014), particularly with the emergence of
alternate tobacco products such as electronic cigarettes (a.k.a. e-cigarettes, electronic nicotine
delivery systems, ENDS) (Delnevo 2014; Maxwell 2010). These products are increasingly
promoted as cigarette alternatives and potentially less harmful than traditional cigarettes (Mejia &
Ling 2010; Regan et al., 2012). Previous studies report that young adults are more likely to report
the concurrent use of tobacco products compared to older adults (Backinger et al., 2008; Fix et
al., 2014), which is a problematic issue as the use of a combination of tobacco products at the
same time, may lead to an increased risk of tobacco-related illnesses, illicit drug use and nicotine
dependence compared to a single tobacco product use (Everett et al., 2000; Bombard et al., 2007;
O’Connor 2012).
The dramatic increase in e-cigarettes use among youth in the United States (US) has also
necessitated a comprehensive examination of the regulatory implications of their spread in the
society, despite the steady decline in cigarette smoking (Barrington-Trimis et al., 2016; Leventhal
et al., 2015; Primack et al., 2015; Unger et al., 2016). This questions the role of e-cigarettes in
tobacco harm reduction (THR) in the society, and the potential to increase smoking uptake among
young people (US Department of Health and Human Services 2016; NASEM 2018). Findings
from the National Youth Tobacco Survey that showed a 78% increase in e-cigarette use among
high school students in 2018 (Cullen et al., 2018) has raised concerns about the increasing
number of tobacco naïve youth initiating e-cigarettes in the US, which may lead to cigarette
smoking transitions (Aleyan et al., 2018; Soneji et al., 2017; Chapman et al., 2018).
A major argument of e-cigarette harm reduction is that harms related to smoking will
reduce through cessations and reductions in smoking frequency, if e-cigarette use is encouraged.
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From this viewpoint, e-cigarettes’ potential for tobacco control promises reduction in the global
burden of disease caused by smoking (Abrams et al., 2018; McNeil et al., 2015; Hajek et al.,
2014). This is based on the assumption that the overall net contribution of e-cigarette use across
populations will be positive, i.e., the number of smokers who quit smoking using e-cigarettes will
be more than the combined numbers of those who relapse to smoking, become dual users (i.e.,
using e-cigarettes and cigarettes), and naïve smokers who initiate smoking after first using ecigarettes (Warner & Mendez 2018). In contrast, the increased popularity of e-cigarettes among
youth, and their potential to lead to cigarette smoking are raising concerns on their role in
expanding the nicotine addiction base among young people, and a subsequent perpetuation of the
tobacco epidemic (Glantz & Bareham 2018; Soneji et al., 2017; Chapman et al., 2018).
Like any new product gaining popularity, there is still a dearth of knowledge about ecigarettes. According to the Surgeon General’s reports; “strategic, comprehensive research is
critical to identify and characterize the potential risks from e-cigarette use” (US Department of
Health and Human Services, 2016). A significant health consequence of tobacco or nicotine use is
their tendency to lead to dependence, and tobacco smoking is reported to be the leading cause of
premature morbidity and mortality in the US (Warren et al., 2014)
In conclusion, factors that affect poly-tobacco use among young people in the US, with
regards to the current tobacco landscape warrants further research. Studies with a longitudinal
design, lengthy follow up, and tobacco use focus in a real-world setting are also needed to
examine e-cigarettes’ THR potential at the population level. The Food and Drug Administration
(FDA) and National Institutes of Health (NIH) initiated the Population Assessment of Tobacco
and Health (PATH) study in 2011, the largest research effort since Congress gave FDA
jurisdiction to regulate tobacco products in 2009 (US Department of Health and Human Services
2018; Hyland et al., 2017). The PATH is a longitudinal study that tracks tobacco use in a
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representative sample of youth and adults in the US using a detailed assessment of all tobacco
products currently in the marketplace (Hyland et al., 2017).
This dissertation aimed to determine the prevalence and identify correlates of polytobacco use among young people (12-34 years) in the United States from Wave 1 (2013-2014) of
the PATH study. It further aimed to examine over a period of 2 years; the trends in e-cigarette
uptake among never cigarette smokers among youth, the transition from e-cigarette mono use to
cigarette smoking among youth and adults; and the transition of dual (e-cigarette/cigarette) use to
mono or no tobacco product use among youth and adults from the Wave 1 (2013-2014), Wave 2
(2014-2015) and Wave 3 (2015-2016) of the PATH study. Finally, this study examined the
transition to sole e-cigarette use or total abstinence versus relapse to exclusive smoking among
adult dual e-cigarette/cigarette users who are nicotine dependent, interested in quitting and
reported a history of a clinical condition such as cardiovascular disease (CVD).
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MANUSCRIPT 1
© Copyright 2019
Correlates of Poly-tobacco use Among Youth and Young adults: Findings from the
Population Assessment of Tobacco and Health Study, 2013-2014.
Abstract
Introduction: Poly-tobacco use is increasing among youth and young adults. This study
examined sociodemographic, tobacco-related, and substance use characteristics of poly-tobacco
use compared to mono-tobacco use among youth and young adults aged 12-34 years in the United
States (U.S). Methods: We conducted a descriptive analysis of 12,898 youth (12-17 years) and
14,931 young adults (18-34 years) from the 2013-2014 Population Assessment of Tobacco and
Health study. Multiple logistic regression modeling was conducted to assess the
sociodemographic, tobacco-related and substance use associations with current (past 30 days)
tobacco product use on a binary scale (poly- versus mono-tobacco use) among tobacco users.
Results: Between 2013 and 2014, 3.6% of youth and 18.3% of young adults were current polytobacco users. Approximately 43% of youth and 48% of young adult tobacco users were polytobacco users, with cigarettes and e-cigarettes being the most common combination. Among
youth and young adult tobacco users, preferred tobacco flavor, heavy drinking, and marijuana use
had higher proportions of poly-tobacco use compared to mono-tobacco use. In the multiple
logistic regression, youth heavy drinkers had statistically significant higher odds of poly-tobacco
use relative to mono-tobacco use. For young adults, males, younger adults (18-24 years), those
with lower levels of educational attainment, those residing in the south, heavy drinkers, and
marijuana users had statistically significant higher odds of poly-tobacco use. Conclusions: Polytobacco use is common among US youth and young adults. Intervention methods explicitly

6

designed to address factors associated with poly-tobacco use among youth and young adults are
warranted.
KEYWORDS: alcohol, drug use, heavy drinking, marijuana, poly-tobacco use, tobacco use, youth,
young adults
Introduction
Poly-tobacco use, the concurrent use of two or more tobacco products, is increasingly
common among youth and young adults (Harrell et al., 2016; Richardson et al., 2014) who are
more likely to be poly users of emerging tobacco products such as hookah, little cigars, cigarillos,
and electronic cigarettes (e-cigarettes) (Kasza et al., 2017; Lee et al., 2014; Lee et al., 2015;
Soneji et al., 2016). The increased use of emerging tobacco products can be partially attributable
to the aggressive marketing practices of the tobacco industry (Mejia and Ling, 2010; Regan et al.,
2012), capitalizing on the misperception of lower harm of these products relative to cigarettes
(Braun et al., 2012; Pearson et al., 2012; Sterling KL et al., 2013). Additionally, the increased
availability, reduced cost, and attractiveness of flavored options are likely contributing to the
popularity of these products among youth in the United States (U.S) (Saunders and Geletko,
2012).
Epidemiological studies in the U.S. show that the use of tobacco products is established
primarily in adolescence, with 9 out of 10 daily cigarette smokers reporting first smoking by age
18 and 99% by age 26 years (USDHHS, 2014). The continued use of these tobacco products can
predispose young people to prolonged nicotine exposure and subsequently nicotine addiction
(USDHHS, 2014), because their developing brain’s reward system is altered, thereby making
them more vulnerable to dependence (McQuown et al., 2007). Studies already suggest that youth
poly-tobacco users have increased symptoms of nicotine dependence compared to mono-tobacco
users (Apelberg et al., 2014). This nicotine dependence may increase the likelihood of young
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poly-tobacco users maturing into adult poly-tobacco users who delay quitting tobacco in
comparison to adult mono-tobacco users (Henningfield et al., 2002; Soneji et al., 2016).
Furthermore, compared to mono-tobacco use, the concurrent use of multiple tobacco products
may also provide challenges for those willing to quit (Bombard et al., 2007; Wetter et al., 2002),
most especially because smoking cessation programs are usually tailored to deal mainly with
cigarettes.
Because of the evolving landscape of tobacco products, coupled with the easy availability
and accessibility of emerging tobacco products; it is particularly necessary to understand the
characteristics of young poly-tobacco users. The increasing diversity of these tobacco products
also highlights the importance of considering the totality of all the tobacco products available to
consumers. Therefore, characterizing young tobacco users who are more likely to be poly-tobacco
users is essential for targeted prevention efforts, as well as for research into the evolution of
tobacco use among poly-tobacco users and challenges they may present to cessation.
Previous research has examined the use of multiple tobacco products using different
definitions ranging from the use of cigarettes and any other tobacco product, the use of 3 or more
tobacco products, whereas some did not include e-cigarettes and hookah among tobacco products
(Bombard et al., 2009; Bombard et al., 2007; Bombard et al., 2008; Lee et al., 2014; Lee et al.,
2015). This study applied an inclusive definition of concurrent use of 2 or more tobacco products
to show the significance of poly-tobacco use regardless of tobacco product type, and emphasize
the epidemic of poly-tobacco use among young people in the U.S. This study used the Population
Assessment of Tobacco and Health (PATH) dataset to investigate the prevalence of poly-tobacco
use among youth and young adults across the range of tobacco products currently available. We
also examined the characteristics of poly-tobacco use compared to mono-tobacco use among
youth (12-17 years) and young adult (18-34 years) tobacco users.
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Methods
Study sample
Study data were from the restricted use files of the PATH study, an ongoing longitudinal
study of tobacco use trajectories and health outcomes, with an overall purpose to inform the Food
and Drug Administration (FDA)’s regulatory policies on tobacco products (USDHHS, 2017).
A detailed methodology for the PATH study is described elsewhere (Hyland et al., 2016;
Kasza et al., 2017). Briefly, the PATH study is a nationally representative sample of 45,971 youth
and adults aged ≥12 years. The PATH study employs a multistage sampling design to produce a
nationally representative sample of the U.S. population. Wave 1 assessment conducted between
2013 and 2014 had a participant response rate among 32,320 adults of 74% and 78.4% among
13,621 youth. Data were collected using audio computer-assisted self-interview (ACASI),
available in English and Spanish. Adult tobacco users, young adults (aged 18–24 years), and
African-Americans were oversampled to make results nationally representative of the general
population (USDHHS, 2017). Survey responses were weighted to adjust for nonresponse, varying
selection probabilities, and oversampling to reflect national estimates.(USDHHS, 2017) This
study was approved by the Institutional Review Board of Florida International University.
Measures
Outcome
The PATH Study inquired about several tobacco products: Bidis and kreteks were also
examined in the youth sample only. We classified subjects into current mono-tobacco users if
they reported the use of only one tobacco product in the past 30 days, or current poly-tobacco
users if they reported the concurrent use of two or more tobacco products in the past 30 days. A
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binary variable was derived to indicate respondents’ tobacco status (0 = mono-tobacco use, 1 =
poly-tobacco use).
Covariates
Using the PATH’s broad theoretical framework of the host, agent, vectors, and
environment, (Hyland et al., 2016) the authors selected covariates most relevant to the study aim,
and those well established in existing tobacco control literature related to tobacco use among
young people (Ambrose et al., 2015; Cohn et al., 2015; Hinds et al., 2017). We classified the
selected items into sociodemographic, tobacco-related and substance use variables.
Sociodemographic variables included in this study were age, sex, sexual orientation,
race/ethnicity, education (young adults), grade (youth), household income (young adults only),
employment status (young adults only) and census region. Self-perception of overall health was
assessed on a 5-point Likert scale, but categorized into four for the current study: excellent, very
good, good and fair/poor due to the small responses in the ‘fair’ and ‘poor’ categories.
Tobacco-related variables examined included; age at first exposure to a tobacco product
regardless of the specific type first used. The variables, preferred tobacco flavor (tobacco
products [come | came] in flavors I like | liked) and advert appeal (the advertising for tobacco
product [appeals | appealed] to me) was assessed for all tobacco products except for cigarettes,
and single binary variables were derived respectively for each (0 = no; 1 = yes).
Substance use variables assessed include; marijuana and other drug use (Ritalin, painkillers,
cocaine, methamphetamine, and heroin). We also assessed excessive alcohol consumption. The
variables used included: 1) heavy drinking derived from the number of days the respondent had
one or more alcoholic drink in last 30 days (<5 /≥ 5 days) and coded as no/yes, and 2) high-risk
drinking derived from the average number of drinks per day. The variable was coded as yes (≥ 4
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drinks/day for females and ≥ 5 drinks/day for males), and no (< 4 drinks/day for females and < 5
drinks/day for males) (USDHHS & USDA, 2015).
Statistical analyses
Initial analysis included descriptive statistics for the overall sample by tobacco status (nontobacco use, mono-tobacco use, and poly-tobacco use) for youth and young adults individually,
by assessing current (past 30 days) tobacco product use. Replicate weights provided by the PATH
study were used to obtain variance estimates using Fay's Method of Balanced Repeated
Replication (BRR), with the Fay coefficient value of 0.3, as recommended by the PATH Study
(USDHHS, 2017) Weighted percentages for sociodemographic, tobacco-related and substance
use characteristics were reported with their confidence intervals (CI). We reported the proportions
of for mono-tobacco products and poly-tobacco use combinations among youth and young adults.
Next, we examined the differences in the proportions of the characteristics and the current use of
tobacco products (poly-tobacco and mono-tobacco) using the Pearson chi-square test. Factors
(sociodemographic, tobacco-related and substance use variables) with P values <0.10 in the
bivariate analyses were included in the binary logistic regression model to determine the
relationship between each variable and poly-tobacco use. Additionally, gender stratification for
the adjusted model was conducted to identify factors associated with poly-tobacco use. We
calculated and reported the adjusted odds ratio (aOR) with the accompanying 95% CI controlling
for the sociodemographic, tobacco-related and substance use variables. A two-sided P value <
0.05 was considered statistically significant. Analyses were conducted using SAS version 9.4
statistical software procedures (SAS Institute Inc., Cary, NC, USA), –PROC SURVEYFREQ and
PROC SURVEYLOGISTIC with BRR method and Fay’s correction of 0.3 – that corrects for the
complex survey design in the PATH study (USDHHS, 2017)
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Results
In the general population of the PATH study, the prevalence of poly-tobacco use was
3.6% among youth and 18.3% among young adults. Mono-tobacco use was 4.8% among youth,
and 19.9% among young adults (Table 1). Among youth mono-tobacco users, current use of
cigarettes was most prevalent at 39.6%, followed by use of e-cigarettes (24.1%), hookah (15.0%),
and cigarillos (9.0%) (Supplementary figure 1). The most common combination of poly-tobacco
use was cigarettes and e-cigarettes (15.1%), followed by the combination of cigarettes and
cigarillos (10.1%) among youth poly-tobacco users. (Supplementary figure 2). The most
prevalent single tobacco product use was current cigarette use (66.1%) among young adult monotobacco users, followed by use of hookah (9.3%), and e-cigarettes (7.5%) (Supplementary figure
3). Similar to youth, the most common combination of poly-tobacco use was cigarettes and ecigarettes (22.5%), followed by cigarettes and cigarillos (9.9%) among young adult poly-tobacco
users. (Supplementary figure 4). The characteristics of tobacco users only (mono- and polytobacco use) were also reported for youth (12-17 years, Supplementary Table 1), and young
adults (18-34 years, Supplementary Table 2). The proportion of poly-tobacco use among youth
tobacco users was 42.9%, and 47.9% among young adult tobacco users, while for mono-tobacco
use, the proportion was 57.1% among youth, and 52.1% among young adults. Among youth (1217 years), a higher proportion of poly-tobacco users were more likely to have a preferred tobacco
flavor, be heavy and high-risk drinkers, and marijuana users compared to mono-tobacco users.
(Supplementary Table 1). For young adults (18-34 years), a higher proportion of poly-tobacco
users were more likely to be aged 18-24 years, males, have a preferred tobacco flavor, and be
heavy drinkers and marijuana users compared to mono-tobacco users (Supplementary Table 2).
Additional characteristics of youth and young adult current tobacco users are available in
Supplementary tables 1 & 2.
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We presented the adjusted ORs for youth (12-17 years) poly-tobacco users relative to
mono-tobacco users in Table 3. Overall, heavy drinkers had significantly higher odds of polytobacco use (aOR: 2.40; CI:1.39-4.16) compared to non-heavy drinkers. Those classified as other
race, compared to non-Hispanic White had significantly lower odds of poly-tobacco use relative
to mono-tobacco use (aOR: 0.40; CI:0.17-0.94). Further, the gender-based analysis shows that
male heavy drinkers had higher odds for poly-tobacco use (aOR: 5.66; CI:1.67-19.18), and those
classified as other race had lower odds for poly-tobacco use (aOR:0.33; CI:0.11-0.97) relative to
mono-tobacco use (Table 3).
In table 4, the adjusted ORs for young adult (18-34 years) poly-tobacco users relative to
mono-tobacco users were reported. Younger (18-24 years), compared to older (25-34 years)
young adults were at higher odds of poly-tobacco use relative to mono-tobacco use (aOR:1.51;
CI:1.13-2.02). Overall, males had higher odds than females of being a poly-tobacco user
(aOR:1.42; CI:1.12-1.80) relative to a mono-tobacco user. Compared to those with a bachelor’s
or advanced degree, those with less than high school or GED (aOR:1.74; CI:1.22-2.49), high
school graduate (aOR:1.85; CI:1.33-3.57), and some college or associate degree (aOR:1.39;
CI:1.03-1.87) had higher odds of poly-tobacco use. Residing in the South was associated with
higher odds of poly-tobacco use compared to those living in the Northeast (aOR:1.75; CI:1.342.23). Additional analysis showed that heavy drinking (aOR:1.43; CI:1.17-1.74), high-risk
drinking (aOR:1.34; CI:1.09-1.66), and marijuana use in the past 30days (aOR:2.10; CI:1.752.51) had significantly higher odds of poly-tobacco use compared to mono-tobacco use. Further,
among young adults, age at first exposure to tobacco product <18 years (aOR:0.41; CI:0.26-0.66);
and age at first tobacco product 18-24 years (aOR:0.60; CI:0.44-0.83) compared to 25-34 years
had lower odds of poly-tobacco use relative to mono-tobacco use. Finally, preferred tobacco
flavor compared to non-preferred tobacco flavor (aOR:0.79; CI:0.65-0.96) also had significantly
lower odds for poly-tobacco use relative to mono-tobacco use (Table 4).
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Following gender stratification, among females, those who identified as lesbian, gay,
bisexual or other compared to heterosexuals (aOR:1.62; 1.16-2.27), and those with less than high
school or GED compared to bachelor’s or advanced degree (aOR:2.04; CI:1.08-3.88) had
significantly higher odds of poly-tobacco use. Among males, younger age of 18-24 years
(aOR:1.94; CI:1.40-2.70) compared to 25-34 years, and high-risk drinking (aOR:1.32; CI:1.031.69) compared to no high-risk drinking had significantly higher odds of poly-tobacco use. Also,
age at first exposure to tobacco product of less than 18 years (aOR: 0.41; CI:0.26-0.66); 18-24
years (aOR:0.58; CI:0.41-0.82) compared to age 25-34 years, and those using a preferred tobacco
flavor (aOR:0.78; CI:0.63-0.95) compared to non-preferred tobacco flavor had significantly lower
odds of poly-tobacco use relative to mono-tobacco use. Additional details about the results of the
multiple logistic regression for the factors associated with both male and female poly-tobacco use
are available in table 4.
Discussion
This is the first study to describe and examine the factors associated with poly-tobacco
use in a large, representative sample of US youth and young adults using the FDA-supported
PATH study. Approximately 4% of youth and 18% of young adults were poly-tobacco users in
the US general population between 2013 and 2014. Our results showed that the most common
combination of poly-tobacco use among youth and young adults was cigarettes and e-cigarettes.
Among current tobacco users, a high proportion of poly-tobacco use among youth (42.9%) and
young adults (47.9%) was observed. We also demonstrated that heavy drinkers and those who
were classified as other race were significantly associated with poly-tobacco use among youth
(12-17 years). Among young adults (18-34 years), younger age, males, lower educational
attainment, residing in the Southern part of the US, heavy- and high-risk drinking, and marijuana
use were significantly associated with poly-tobacco use. Our results signify a shift in the tobacco
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epidemic among young people trending towards the use of multiple tobacco products (Fix et al.,
2014), which is concerning because poly-tobacco use is found to increase the risk of illicit drug
use, and nicotine addiction compared to the use of a single tobacco product (Bombard et al.,
2009). Additionally, the distinct characteristics of poly-tobacco users compared to mono-tobacco
users, suggest where interventions may be applied to address this particular issue.
Previous epidemiological research has consistently found males to have higher odds of
tobacco use (Butler et al., 2016; Lee et al., 2014; Lee et al., 2015). The current study extends this
observation to poly-tobacco use where males were at significantly higher odds (42%) for polytobacco use among young adult tobacco users. Although in the current study males and females in
both age groups had almost comparable proportions of mono-tobacco use, the proportion of polytobacco use was much higher among males. This interesting finding may follow the known stages
of the cigarette smoking epidemic, as earlier stages of the epidemic found that males had higher
prevalence rates of cigarette smoking compared to females (Thun et al., 2012). However, the
rates of cigarette use between males and females narrowed as the epidemic advanced (Thun et al.,
2012). The pattern of poly-tobacco use we observed may set up a new stage of another tobacco
epidemic, where females eventually catch up with rates comparable to males in the future.
Using data from the National Adult Tobacco Survey, the Centers for Disease Control and
Prevention (CDC) and the FDA, in 2013-2014, demonstrated that US young adults aged 18-24
years had the highest prevalence of emerging tobacco product use including hookah and ecigarettes (Hu et al., 2016). Moreover, there is evidence that young adulthood is increasingly
becoming a time of initiation of multiple tobacco products, particularly new ones (Hu et al.,
2016). In the current study, the high prevalence of poly-tobacco use among those aged 18-24
years may, in fact, have resulted from the increased use of these emerging tobacco products due
to their attractiveness to youth, aggressive marketing by the industry, and the reduced harm
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perception associated with their use relative to cigarettes (Braun et al., 2012; Mejia and Ling,
2010; Pearson et al., 2012; Regan et al., 2012; Sterling KL et al., 2013).
Emerging research demonstrates that tobacco use is more prevalent among lesbians, gays,
and bisexuals (LGB) compared to heterosexuals (Dilley et al., 2008; Hu et al., 2016; Lee et al.,
2009). Our study extends this literature showing that young adult lesbian and bisexual female
tobacco users have a 62% higher odd of poly-tobacco use compared to mono-tobacco use. It is
posited that this finding may be due to a variety of psychosocial factors, ranging from higher
levels of alcohol consumption, depression, discrimination, homophobia, low socioeconomic
status, stigma, and stress (Blosnich et al., 2013; Lee et al., 2009; Pelster et al., 2015).
Furthermore, they are more likely to be targeted by the tobacco industry’s marketing strategies
(Blosnich et al., 2013; Dilley et al., 2008; Lee et al., 2009; Pelster et al., 2015). LGBs are also
more likely to be surrounded by smokers; which is associated with a higher likelihood of tobacco
use, a barrier to cessation and leads to an increase in morbidity and mortality in these individuals
(Cochran et al., 2013; Oberg et al., 2011; Perales et al., 2017). Research reports that lesbian and
bisexual females are more likely to smoke cigarettes and use hookah compared to heterosexual
females or gay males (Dilley et al., 2008; Emory et al., 2016; Gamarel et al., 2016). Reducing
poly-tobacco use in this particular group of tobacco users should be a priority.
Our results also indicate that young adults residing in the South compared to the
Northeast had a 75% higher odd for poly-tobacco use relative to mono-tobacco use. A survey
conducted in the US during 2013 – 2014 found that those residing in the South reported the
highest prevalence of the use of any tobacco product (Hu et al., 2016). It has also been described
that those living in the South tend to use multiple tobacco products, such as cigarettes and
smokeless tobacco (USDHHS, 2014). The regional disparities observed in poly-tobacco use may
be due to a variety of factors such as demographics, variations in tobacco control programs and
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policies, and regional differences in tobacco industry marketing and promotion practices (King et
al., 2012)
Consistent with the literature (Cohn et al., 2017; Wetter et al., 2002), we also found that
youth and young adults tobacco users who used alcohol had higher odds of poly-tobacco use
relative to mono-tobacco use. Additionally, those aged 18-34 years had a 2-fold higher odds of
marijuana use. Previous research demonstrated that young poly-tobacco users were more likely to
engage in heavy drinking and marijuana use than mono-tobacco users (Cohn et al., 2017; Soneji
et al., 2016). The utilization of alcohol and marijuana has been shown to contribute to greater
nicotine dependence and increased difficulty with quitting in late adulthood (Cohn et al., 2015;
Kahler et al., 2009). Studies suggest that tobacco, alcohol, and marijuana use are risk factors that
co-occur among youth and young adults and have the potential to serve as “gateway drugs” to
each other (Kandel and Kandel, 2014; Sosensky and Doyle, 2016). Given that substance use and
tobacco use often co-occur, substance use may serve as a hindrance to tobacco control efforts,
particularly among young people thereby contributing to the poly-tobacco use epidemic.
Therefore, coping mechanisms for dealing with the bait of heavy alcohol consumption, and
substance use should be incorporated into cessation interventions.
Although preferred tobacco flavor was associated with lower odds of poly-tobacco use in
our study, the proportion of those who had a preferred tobacco product among tobacco users was
much higher among youth and young adult poly-tobacco users. This finding contributes more
evidence to the problem of the flavoring of unregulated tobacco products accessible to young
people (Ambrose et al., 2015; Harrell et al., 2017). Flavor restrictions do not apply to cigars, ecigarettes, and hookah, and these may appeal to young people by concealing the harsh taste of
tobacco for new and inexperienced smokers (Carpenter et al., 2005; Soneji et al., 2016), and
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incidentally lead to an increase in the use of tobacco products which may also be contributory to
the prevalence of poly-tobacco use among young people.
Additionally, youth and young adults have the option of choosing from a wide array of
tobacco products that can help with circumventing smoking bans or smoke-free laws. These
tobacco products also have different routes of administration which may serve as a marker for
increased nicotine dependence (Agaku and Ayo-Yusuf, 2014), thereby promoting increased polytobacco product use (Kaufman et al., 2015). It is disturbing for young persons, particularly those
before the age of maturity, to become addicted to nicotine; and it is likely that this trend will
continue (USDHHS, 2014; Kozlowski and Sweanor 2017) As a result, tobacco control efforts
should be vigorously intensified to halt this public health burden. These findings suggest the need
to develop targeted control policies responsive to the unique characteristics associated with polytobacco use among young people with the goal of reducing the prevalence of poly-tobacco use
among this subpopulation in the US.
Major strengths of this study include the use of a large national sample of youth and young
adults not restricted to high school or college students. An additional strength is the assessment of
the new and emerging tobacco products such as e-cigarettes and hookah. There are however some
limitations to be considered. First, the cross-sectional analysis does not allow the observation of
causality of the factors associated with poly-tobacco use. Second, this study relied on participant
self-reports of tobacco use and age at first exposure to a tobacco product, which predisposes to
recall bias. However, studies show that self-reports on tobacco use are reliable and provide valid
estimates in the US (Brener et al., 2003). Finally, due to the relatively small sample sizes for nonHispanic Asians, American Indian/Alaska Natives, Native Hawaiians, Pacific Islanders, and
multi-racial groups; these were collapsed into one category. Hence estimates for these racial
groups were not possible in the current study.
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Conclusions
Our results demonstrate that a significant proportion of youth and young adults are polytobacco users regardless of tobacco product type. Furthermore, the rates are even much higher
among tobacco users. It is glaring that poly-tobacco use epidemic in the US poses a direct threat
to tobacco control, both in prevention and cessation efforts, majorly because of the easy
accessibility, and flavoring of some of these tobacco products. The current tobacco control
framework is inadequate to address this epidemic due to their inconsistency with poly-tobacco
use among young people for tobacco products that are not adequately regulated by the FDA.
Population-level interventions directed at all forms of tobacco product use, including taxation of
tobacco products, comprehensive smoke-free laws, reducing flavor appeal and access to tobacco
products, in addition to the FDA’s regulation of all tobacco products, will be particularly critical
in reducing the burden of poly-tobacco use among young people in the US.
References
Agaku IT, Ayo-Yusuf OA. The Effect of Exposure to Pro-Tobacco Advertising on
Experimentation With Emerging Tobacco Products Among U.S. Adolescents. Health
Educ Behav. 2014;41(3):275-280.
Ambrose BK, Day HR, Rostron B, Conway, K.P., Borek, N., Hyland, A., Villanti, A.C., 2015.
Flavored Tobacco Product Use Among US Youth Aged 12-17 Years, 2013-2014. JAMA
314(17):1871-1873. doi:10.1001/jama.2015.13802.
Apelberg BJ, Corey CG, Hoffman AC, Schroeder MJ, Husten CG, Caraballo RS, Backinger CL.
Symptoms of tobacco dependence among middle and high school tobacco users: results
from the 2012 National Youth Tobacco Survey. Am J Prev Med. 2014;47(2 Suppl 1):S414. doi:10.1016/j.amepre.2014.04.013.
Blosnich J, Lee JG, Horn K. A systematic review of the aetiology of tobacco disparities for
sexual minorities. Tob Control. 2013;22(2):66-73. doi:10.1136/tobaccocontrol-2011050181.
Bombard JM, Pederson LL, Koval JJ, O'Hegarty M. How are lifetime polytobacco users different
than current cigarette-only users? Results from a Canadian young adult population.
Addict Behav. 2009;34(12):1069-1072. doi: 10.1016/j.addbeh.2009.06.009.

19

Bombard JM, Pederson LL, Nelson DE, Malarcher AM. Are smokers only using cigarettes?
Exploring current polytobacco use among an adult population. Addict Behav.
2007;32(10):2411-2419. doi:10.1016/j.addbeh.2007.04.001.
Bombard JM, Rock VJ, Pederson LL, Asman KJ. Monitoring polytobacco use among
adolescents: do cigarette smokers use other forms of tobacco? Nicotine Tob Res.
2008;10(11):1581-1589. doi: 10.1080/14622200802412887.
Braun R, Glassman T, Wohlwend J, Whewell A, Reindl D. Hookah Use Among College Students
from a Midwest University. J Community Health. 2012;37(2):294-298. doi:
10.1007/s10900-011-9444-9.
Brener ND, Billy JO, Grady WR. Assessment of factors affecting the validity of self-reported
health-risk behavior among adolescents: evidence from the scientific literature. J Adolesc
Health. 2003;33(6):436-457. doi: http://dx.doi.org/10.1016/S1054-139X(03)00052-1
Butler KM, Ickes MJ, Rayens MK, Wiggins AT, Hahn EJ. Polytobacco Use Among College
Students. Nicotine Tob Res. 2016;18(2), 163-169. doi: 10.1093/ntr/ntv056.
Carpenter CM, Wayne GF, Pauly JL, Koh HK, Connolly GN. New cigarette brands with flavors
that appeal to youth: tobacco marketing strategies. Health Aff (Millwood).
2005;24(6):1601-1610. doi: 10.1377/hlthaff.24.6.1601.
Cochran SD, Bandiera FC, Mays VM. Sexual orientation-related differences in tobacco use and
secondhand smoke exposure among US adults aged 20 to 59 years: 2003-2010 National
Health and Nutrition Examination Surveys. Am J Public Health. 2013;103(10):18371844. doi: 10.2105/AJPH.2013.301423.
Cohn A, Villanti A, Richardson A, Rath JM, Williams V, Stanton C, Mermelstein R. The
association between alcohol, marijuana use, and new and emerging tobacco products in a
young adult population. Addict Behav. 2015;48:79-88.
doi:10.1016/j.addbeh.2015.02.005.
Cohn AM, Ehlke SJ, Cobb CO, Soule EK. Hookah tobacco smoking in a large urban sample of
adult cigarette smokers: Links with alcohol and poly-tobacco use. Addict Behav.
2017;68:1-5. doi:10.1016/j.addbeh.2016.12.012.
Dilley JA, Spigner C, Boysun MJ, Dent CW, Pizacani BA. Does tobacco industry marketing
excessively impact lesbian, gay and bisexual communities? Tob Control. 2008;17(6):385390. doi:10.1136/tc.2007.024216.
Emory K, Kim Y, Buchting F, Vera L, Huang J, Emery SL. Intragroup Variance in Lesbian, Gay,
and Bisexual Tobacco Use Behaviors: Evidence That Subgroups Matter, Notably
Bisexual Women. Nicotine Tob Res. 2016;18(6):1494-1501. doi: 10.1093/ntr/ntv208.
Fix BV, O'Connor RJ, Vogl L, Smith D, Bansal-Travers M, Conway KP, Ambrose B, Yang L,
Hyland A. Patterns and correlates of polytobacco use in the United States over a decade:
NSDUH 2002-2011. Addict Behav. 2014;39(4):768-781. doi:
10.1016/j.addbeh.2013.12.015.

20

Gamarel KE, Kahler CW, Lee JH, Reisner SL, Mereish EH, Matthews AK, Operario D. Sexual
orientation disparities in smoking vary by sex and household smoking among US adults:
Findings from the 2003-2012 National Health and Nutrition Examination Surveys. Prev
Med. 2016;82:1-6. doi:10.1016/j.ypmed.2015.10.008.
Harrell MB, Loukas A, Jackson CD, Marti CN, Perry CL. Flavored Tobacco Product Use among
Youth and Young Adults: What if Flavors Didn't Exist? Tob Regul Sci. 2017;3(2):168173. doi: 10.18001/TRS.3.2.4.
Harrell PT, Naqvi SM, Plunk AD, Ji M, Martins SS. Patterns of youth tobacco and polytobacco
usage: The shift to alternative tobacco products. Am J Drug Alcohol Abuse.
2017;43(6):694-702. doi: 10.1080/00952990.2016.1225072.
Henningfield JE, Rose CA, Giovino GA. Brave new world of tobacco disease prevention:
promoting dual tobacco-product use? Am J Prev Med. 2002;23(3):226-228.
Hinds JT, Li X, Loukas A, Pasch KE, Perry CL. Flavored Cigars Appeal to Younger, Female, and
Racial/Ethnic Minority College Students. Nicotine Tob Res. 2017. doi:10.1093/ntr/ntx041
Hu SS, Neff L, Agaku IT, Cox S, Day HR, Holder-Hayes E, King BA. Tobacco Product Use
Among Adults - United States, 2013-2014. MMWR Morb Mortal Wkly Rep.
2016;65(27):685-691. doi: 10.15585/mmwr.mm6527a1.
Hyland A, Ambrose BK, Conway KP, Borek N, Lambert E, Carusi, C, et al. Design and methods
of the Population Assessment of Tobacco and Health (PATH) Study. Tob Control 26(4),
371-378.
Kahler CW, Borland R, Hyland A, McKee SA, Thompson ME, Cummings KM. Alcohol
consumption and quitting smoking in the International Tobacco Control (ITC) Four
Country Survey. Drug Alcohol Depend. 2009;100(3):214-220. doi:
10.1016/j.drugalcdep.2008.10.006.
Kandel DB, Kandel ER. A molecular basis for nicotine as a gateway drug. N Engl J Med.
2014;371(21):2038-2039. doi: 10.1056/NEJMsa1405092.
Kasza KA, Ambrose BK, Conway KP, Borek N, Taylor K, Goniewicz ML, et al. TobaccoProduct Use by Adults and Youths in the United States in 2013 and 2014. N Engl J Med.
2017;376(4):342-353. DOI: 10.1056/NEJMsa1607538.
Kaufman A, Land S, Parascandola M, Augustson E, Backinger C. Tobacco use transitions in the
United States: The National Longitudinal Study of Adolescent Health. Prev Med.
2015;81:251-257. doi: 10.1016/j.ypmed.2015.08.026.
King BA, Dube SR, Tynan MA. Current tobacco use among adults in the United States: findings
from the National Adult Tobacco Survey. Am J Public Health. 2012:102(11), e93-e100.
doi: 10.2105/AJPH.2012.301002.
Kozlowski LT, Sweanor DT. Young or adult users of multiple tobacco/nicotine products urgently
need to be informed of meaningful differences in product risks. Addict Behav. 2017.
doi10.1016/j.addbeh.2017.01.026.

21

Lee JG, Griffin GK, Melvin CL. Tobacco use among sexual minorities in the USA, 1987 to May
2007: a systematic review. Tob Control. 2009;18(4):275-282. doi:
10.1136/tc.2008.028241.
Lee Y, Hebert C, Nonnemaker J, Kim A. Multiple tobacco product use among adults in the
United States: Cigarettes, cigars, electronic cigarettes, hookah, smokeless tobacco, and
snus. Prev Med. 2014;62:14-19. doi: 10.1016/j.ypmed.2014.01.014.
Lee YO, Hebert CJ, Nonnemaker JM, Kim AE. Youth tobacco product use in the United States.
Pediatrics. 2015;135(3), 409-415. doi: 10.1542/peds.2014-3202.
McQuown SC, Belluzzi JD, Leslie FM. Low dose nicotine treatment during early adolescence
increases subsequent cocaine reward. Neurotoxicol Teratol. 2007;29(1):66-73. DOI:
10.1016/j.ntt.2006.10.012.
Mejia AB, Ling PM., 2010. Tobacco industry consumer research on smokeless tobacco users and
product development. Am J Public Health. 2010;100(1):78-87. doi:
10.2105/AJPH.2008.152603.
Oberg M, Jaakkola MS, Woodward A, Peruga A, Prüss-Ustün A. Worldwide burden of disease
from exposure to second-hand smoke: a retrospective analysis of data from 192 countries.
Lancet. 2011;377(9760):139-146.
Pearson JL, Richardson A, Niaura RS, Vallone DM, Abrams DB. e-Cigarette awareness, use, and
harm perceptions in US adults. Am J Public Health. 2012; 102(9):1758-1766. doi:
10.2105/AJPH.2011.300526.
Pelster AD, Fisher CM, Irwin JA, Coleman JD, McCarthy MA. Tobacco Use and Its Relationship
to Social Determinants of Health in LGBT Populations of a Midwestern State. LGBT
Health. 2015;2(1):71-76. doi: 10.1089/lgbt.2014.0012.
Perales J, Checa I, Espejo B. Current active and passive smoking among adults living with same
sex partners in Spain. Gac Sanit. 2017;pii: S0213-9111(17),30099-30097. doi:
10.1016/j.gaceta.2017.03.006.
Regan AK, Dube SR, Arrazola R. Smokeless and flavored tobacco products in the U.S.: 2009
Styles survey results. Am J Prev Med. 2012;42(1):29-36. doi:
10.1016/j.amepre.2011.08.019.
Richardson A, Williams V, Rath J, Villanti A, Vallone D. The Next Generation of Users:
Prevalence and Longitudinal Patterns of Tobacco Use Among US Young Adults. Am J
Public Health. 2014;104(8):1429-1436. doi: 10.2105/AJPH.2013.301802.
Saunders C, Geletko K. Adolescent cigarette smokers' and non-cigarette smokers' use of
alternative tobacco products. Nicotine Tob Res. 2012;14(8):977-985. doi:
10.1093/ntr/ntr323.
Soneji S, Sargent J, Tanski S. Multiple tobacco product use among US adolescents and young
adults. Tob Control 25(2), 174-180. doi:10.1136/tobaccocontrol-2014-051638.

22

Sosensky MM, Doyle EA. Polytobacco Use Among Adolescents. Pediatr Nurs. 2016;42(3):150154.
Sterling KL, Berg CJ, Thomas AN. Factors associated with little cigar and cigarillo use among
college students. Am J Health Behav. 2013;37(3):325 - 333. doi: 10.5993/AJHB.37.3.5.
Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second
century. Tob Control. 2012;21(2):96-101. doi: 10.1136/tobaccocontrol-2011-050294.
US Department of Health and Human Services, 2014. The Health Consequences of Smoking 50
years of progress: A report of the surgeon general. Atlanta, GA: U.S. Department of
Health and Human Services, Centers for Disease Control and Prevention, National Center
for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
(Accessed June 9, 2017).
U.S. Department of Health and Human Services and U.S. Department of Agriculture, 2015.
Dietary Guidelines for Americans 2015 - 2020. Retrieved from
https://health.gov/dietaryguidelines/2015/guidelines/acknowledgments/. (Accessed
August 17 2017).
United States Department of Health and Human Services. National Institutes of Health. National
Institute on Drug Abuse, and United States Department of Health and Human Services.
Food and Drug Administration. Center for Tobacco Products. Population Assessment of
Tobacco and Health (PATH) Study [United States] Restricted-Use Files. ICPSR36231v13. Ann Arbor, MI: Inter-university Consortium for Political and Social Research
[distributor], 2017-06-19. https://doi.org/10.3886/ICPSR36231.v13.
Wetter DW, McClure JB, de Moor C, Cofta-Gunn L, Cummings S, Cinciripini PM, Gritz ER.
Concomitant use of cigarettes and smokeless tobacco: prevalence, correlates, and
predictors of tobacco cessation. Prev Med. 2002;34(6):638-648.
https://doi.org/10.1006/pmed.2002.1032.

23

Tables and figures

Table 1 – Characteristics of Youths (12-17 years) by Tobacco Status¶: PATH Study, 2013-2014 (N= 12,898)
Total, weighted
Non-tobacco use,
Mono-tobacco use,
Poly-tobacco use,
%
weighted % (95% CI) weighted % (95% CI)
weighted % (95% CI)
Total
12898* (100.0)
91.6 (90.9-92.1)
4.8 (4.4 – 5.3)
3.6 (3.3 – 4.0)
Sociodemographic
variables
Age group (y)
12-14
6541 (49.9)
48.6 (47.7-49.5)
0.9 (0.7-1.0)
0.5 (0.3-0.6)
15-17
6357 (50.1)
42.9 (42.1-43.8)
4.0 (3.6-4.4)
3.2 (2.9-3.5)
Gender
Male
6538 (50.7)
46.0 (45.2-46.9)
2.3 (2.1-2.6)
2.3 (2.1-2.7)
Female
6360 (49.3)
45.5 (44.6-46.4)
2.5 (2.2-2.8)
1.3 (1.1-1.5)
Sexual Orientation
Heterosexual
7846 (93.1)
82.7 (81.7-83.6)
5.8 (5.2-6.4)
4.6 (4.2-5.2)
Lesbian,
Gay,
585 (6.9)
5.4 (4.8-5.9)
0.9 (0.7-1.2)
0.6 (0.4-0.8)
Bisexual, Other
Race/Ethnicitya
Non-Hispanic White
6150 (54.7)
49.3 (48.4-50.2)
2.9 (2.5-3.3)
2.5 (2.2-2.8)
Non-Hispanic Black
1697 (13.6)
12.7 (12.1-13.2)
0.7 (0.6-0.9)
0.3 (0.2-0.4)
Other
1164 (9.3)
8.7 (8.2-9.2)
0.3 (0.2-0.4)
0.3 (0.2-0.4)
Hispanic
3662 (22.4)
20.9 (20.2-21.6)
0.9 (0.8-1.1)
0.6 (0.5-0.8)
Grade in schoolb
5-8
4856 (37.8)
37.1 (36.3-38.0)
0.5 (0.4-0.6)
0.2 (0.2-0.4)
9-12
7524 (60.2)
53.0 (52.1-53.8)
4.1 (3.7-4.5)
3.1 (2.8-3.5)
Other
250 (2.0)
1.5 (1.3-1.8)
0.3 (0.2-0.4)
0.2 (0.1-0.3)
Money received per
week
None
4195 (33.3)
31.7 (30.7-32.7)
0.9 (0.7-1.0)
0.7 (0.5-0.9)
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P value
<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

$10
$11-$50
>$50
US census region
Northeast
Midwest
South
West
Self-perception of
overall health
Excellent
Very good
Good
Fair-Poor
Tobacco-related
variables
Age at first exposure
to tobacco product (y)
<14
15-17
Preferred tobacco
flavor
Yes
No
Advert appeal
Yes
No
Substance use
variables
Heavy drinkingc
Yes

3791 (29.0)
3424 (26.9)
1340 (10.8)

27.4 (26.5-28.3)
23.9 (23.1-24.7
8.5 (8.0-9.1)

1.0 (0.9-1.3)
1.6 (1.4-1.9)
1.3 (1.1-1.5)

0.6 (0.5-0.7)
1.4 (1.2-1.6)
1.0 (0.8-1.2)

1939 (16.9)
2798 (21.6)
4880 (37.5)
3281 (24.0)

15.3 (14.7-15.9)
19.6 (18.9-20.3)
34.3 (33.5-35.1)
22.3 (21.623.0)

0.9 (0.7-1.1)
1.2 (1.0-1.4)
1.8 (1.5-2.2)
0.9 (0.7-1.1)

0.7 (0.5-0.9)
0.8 (0.7-1.1)
1.3 (1.1-1.5)
0.8 (0.6-1.0)

0.1015

<0.0001
7524 (60.2)
3501 (27.1)
1458 (10.4)
355 (2.4)

56.3 (55.0-57.5)
24.1 (23.2-25.0)
9.2 (8.5-9.9)
2.0 (1.8-2.3)

2.2 (1.9-2.6)
1.8 (1.6-2.0)
0.6 (0.5-0.8)
0.2 (0.1-0.3)

1.7 (1.4-1.9)
1.2 (1.0-1.4)
0.6 (0.5-0.8)
0.2 (0.1-0.2)

<0.0001
1100 (40.2)
1535 (59.8)

29.1 (27.4-30.9)
29.5 (27.8-31.3)

7.2 (6.2-8.3)
16.3 (14.8-18.0)

3.9 (3.1-4.8)
13.9 (12.7-15.3)
0.1459

568 (67.4)
265 (32.6)

-

31.3 (28.0-34.7)
13.0 (10.7-15.7)

36.2 (33.0-39.6)
19.4 (16.7-22.4)

111 (12.4)
723 (87.6)

-

6.9 (5.4-8.9)
37.3 (34.0-40.8)

5.5 (4.1-7.2)
50.3 (46.8-53.7)

223 (24.5)

8.3 (6.5-10.5)

5.9 (4.6-7.7)

10.3 (8.3-12.7)

0.0030

<0.0001
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No
High-risk drinkingd
Yes
No
Marijuana usee
Within the past 30days
>30days
Other substance usee
Within the past 30days
>30days

696 (75.5)

47.2 (44.0-50.5)

16.1 (13.6-18.8)

12.2 (10.2-14.5)
<0.0001

253 (30.1)
582 (69.9)

10.0 (7.9-12.7)
43.1 (39.8-46.6)

7.6 (5.8-10.0)
15.1 (12.6-17.9)

12.4 (10.1-15.2)
11.7 (9.7-14.2))

631 (38.1)
1065 (61.9)

14.5 (12.6-16.6)
43.6 (41.3-46.0)

11.2 (9.8-12.8)
9.8 (8.4-11.4)

12.3 (10.6-14.3)
8.5 (7.2-9.9)

493 (39.6)
765 (60.4)

33.9 (31.1-36.9)
42.2 (39.0-45.5)

2.8 (1.9-3.9)
8.1 (6.7-9.8)

2.9 (2.1-4.0)
10.1 (8.4-12.0)

<0.0001

<0.0001

Note: PATH = Population Assessment of Tobacco and Health, CI = confidence interval ¶ Tobacco status = current (past 30 days) tobacco product use;
*753 missing due to missing responses in youth. Unweighted sample size and weighted percentages are presented; percentages are weighted to represent
youth population. aOther refers to Non-Hispanic American Indian or Alaska Native, Non-Hispanic Asian/Native Hawaiian or Other Pacific Islander and
persons with multiple races. bOther refers to college, vocational/tech school, not enrolled, homeschooled, ungraded (schools where students are not
assigned to a particular grade). cAnswered by respondents who have ever used alcohol and used alcohol in the past 30 days. dAnswered by respondents
who have ever used alcohol, used in the past 30 days and drank on one or more days. eAnswered by respondents who have ever used marijuana or other
substance use (Ritalin, painkillers, cocaine, methamphetamine, and heroin).
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Table 2 – Characteristics of Young Adults (18-34 years) by Tobacco Status¶: PATH Study, 2013-2014 (N= 14,931)
Total,
Non-tobacco use,
Mono-tobacco use,
Poly-tobacco use,
weighted %
weighted % (95%
weighted % (95% CI)
weighted % (95%
CI)
CI)
Total
14931*(100.0)
61.7 (60.4-63.0)
19.9 (19.2 – 20.8)
18.3 (46.6-49.2)
Sociodemographic variables
Age group (y)
18-24
8843 (42.6)
25.5 (24.6-26.4)
7.9 (7.4-8.3)
9.3 (8.7-9.9)
25-34
6081 (57.4)
36.2 (35.2-37.3)
12.1 (11.5-12.7)
9.1 (8.6-9.6)
Gender
Male
7521 (49.8)
26.7 (25.6-27.9)
10.9 (10.3-11.4)
12.3 (11.6-13.0)
Female
7410 (50.2)
35.0 (34.2-35.8)
9.1 (8.6-9.6)
6.1 (5.7-6.5)
Sexual Orientation
Heterosexual
13351 (92.3)
57.6 (56.2-59.0)
18.2 (17.4-19.0)
16.5 (15.7-17.3)
Lesbian, Gay, Bisexual, Other
1380 (7.7)
3.9 (3.4-4.5)
1.8 (1.6-2.1)
2.0 (1.7-2.2)
a
Race/Ethnicity
Non-Hispanic White
8134 (57.2)
33.5 (32.1-35.0)
12.3 (11.7-13.0)
11.4 (10.7-12.2)
Non-Hispanic Black
2137 (12.6)
7.5 (7.0-8.2)
2.6 (2.4-2.9)
2.5 (2.2-2.8)
Other
1356 (10.0)
7.1 (6.4-7.9)
1.4 (1.2-1.7)
1.5 (1.3-1.7)
Hispanic
3196 (20.1)
13.5 (12.7-14.4)
3.6 (3.3-3.9)
3.0 (2.7-3.3)
Education
Less than high school or GED
2693 (14.5)
6.6 (6.0-7.2)
4.0 (3.7-4.3)
3.9 (3.6-4.2)
High school graduate
3810 (24.0)
13.8 (13.1-14.5)
5.2 (4.8-5.5)
5.0 (4.6-5.4)
Some college or associate’s
5826 (36.8)
21.9 (20.7-23.1)
7.6 (7.2-8.1)
7.3 (6.9-7.8)
degree
Bachelor’s degree or advanced
2602 (24.7)
19.4 (18.5-20.4)
3.1 (2.7-3.6)
2.1 (1.9-2.4)
degree
Household incomeb
<$25,000
6686 (38.5)
20.7 (19.5-21.8)
8.8 (8.3-9.4)
9.0 (8.4-9.6)
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P value

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

$25,000-$74,999
≥$75,000
Not reported
Employment status
Full-time (≥35hours per week)
Part-time (15-24hours per
week)
Part-time (<15hours per week)
Don’t currently work for pay
US census region

4561 (32.9)
2303 (19.5)
1381 (9.1)

20.7 (19.6-21.8)
14.2 (13.3-15.3)
6.1 (5.5-6.8)

6.6 (6.2-7.1)
3.0 (2.7-3.3)
1.5 (1.3-1.8)

5.6 (5.2-6.1)
2.3 (2.1-2.6)
1.4 (1.2-1.6)

6536 (49.9)
2846 (17.0)

30.9 (29.7-32.2)
10.4 (9.5-11.4)

10.3 (9.6-10.9)
3.2 (2.9-3.6)

8.7 (8.1-9.2)
8.8 (8.2-9.5)

1027 (6.3)
4421 (26.8)

4.0 (3.5-4.6)
16.3 (15.4-17.2)

1.1 (0.9-1.3)
5.4 (5.0-5.9)

3.1 (2.7-3.5)
5.1 (4.8-5.9)

Northeast
Midwest
South
West
Self-perception of overall
health
Excellent
Very good
Good
Fair-Poor
Tobacco-related variables
Age at first exposure to
tobacco product (y)
<18
18-24
25-34
Preferred tobacco flavor
Yes
No
Advert appeal

2237 (16.7)
3458 (21.4)
5691 (37.5)
3545 (24.4)

0.0627

<
0.00
01
10.0 (9.2-10.8)
12.9 (12.0 -13.9)
22.4 (20.8-24.1)
16.4 (14.9-18.1)

3.9 (3.4-4.3)
4.5 (4.1-4.8)
7.6 (7.1-8.2)
4.0 (3.6-4.5)

2.8 (2.5-3.2)
4.1 (3.7-4.5)
7.5 (6.9-8.0)
4.0 (3.5-4.6)
<0.0001

2856 (21.1)
5508 (38.7)
5052 (31.6)
1496 (8.6)

15.1 (14.1-16.2)
25.8 (24.6-27.0)
17.0 (16.0-18.0)
3.9 (3.4-4.4)

3.2 (2.9-3.5)
6.9 (6.5- 7.3)
7.4 (6.9-7.8)
2.5 (2.2-2.8)

2.7 (2.5-3.0)
6.0 (5.6-6.5)
7.3 (6.8-7.7)
2.3 (2.1-2.5)
<0.0001

1338 (11.7)
7328 (58.0)
2889 (30.4)

6.1 (5.4-7.0)
25.4 (24.1-26.6)
8.8 (8.0-9.5)

3.1 (2.7-3.4)
15.4 (14.6-16.1)
10.7 (10.0-11.4)

2.5 (2.2-2.8)
17.2 (16.4-18.1)
10.9 (10.3-11.6)
0.0023

3960 (62.1)
2310 (37.9)

7.7 (6.9-8.7)
4.6 (3.9-5.3)

20.4 (19.2-21.7)
10.6 (9.7-11.5)

33.9 (32.4-35.5)
22.8 (21.6-24.0)
0.7588
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Yes
No
Substance use variables
Heavy drinkingc
Yes
No
High-risk drinkingd
Yes
No
Marijuana usee
Within the past 30days
>30days
Other substance usee
Within the past 30days
>30days

484 (7.5)
5785 (92.5)

0.8 (0.6-1.2)
11.4 (10.3-12.6)

2.4 (2.0-2.9)
28.6 (27.3-30.0)

4.2 (3.7-4.8)
52.5 (51.1-53.8)

4601 (51.6)
4148 (48.4)

25.1 (23.7-26.5)
29.3 (27.9-30.6)

12.3 (11.6-13.1)
10.4 (9.7-11.1)

14.2 (13.4-15.0)
8.7 (8.2-9.3)

0.0001

<0.0001
2362 (22.5)
6308 (77.5)

7.4 (6.6-8.4)
46.7 (45.2-48.3)

6.8 (6.3-7.4)
15.9 (15.1-16.7)

8.3 (7.7-8.9)
14.8 (14.0-15.6)

8.9 (8.2-9.6)
19.3 (18.3-20.4)

15.8 (15.1-16.7)
16.5 (15.5-17.5)

2.6 (2.1-3.3)
24.7 (23.2-26.3)

3.4 (2.9-3.9)
30.3 (28.7-31.9)

<0.0001
2912 (30.8)
5163 (69.2)

6.1 (5.4-6.8)
33.4 (31.7-35.2)

0.0114
473 (11.3)
3878 (88.7)

5.3 (4.3-6.4)
33.7 (31.7-35.8)

Note: PATH = Population Assessment of Tobacco and Health, CI = confidence interval ¶ Tobacco status = current (past 30 days) tobacco product use;
*526 missing due to missing responses in young adults; unweighted sample size and weighted percentages are presented. aBlack persons and young adults
(18–24) were oversampled; percentages are weighted to represent young adult populations; Other refers to Non-Hispanic American Indian or Alaska
Native, Non-Hispanic Asian/Native Hawaiian or Other Pacific Islander and persons with multiple races. bHousehold income includes those who refused
to report their income. cAnswered by respondents who have ever used alcohol and used alcohol in the past 30 days. dAnswered by respondents who have
ever used alcohol, used in the past 30 days and drank on one or more days. eAnswered by respondents who have ever used marijuana or other substance
use (Ritalin, painkillers, cocaine, methamphetamine, and heroin).
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Table 3 – Multivariable associations¶ for poly-tobacco use compared to mono-tobacco use among youths (12-17 years) past
30days tobacco users overall, and stratified by gender: PATH Study, 2013-2014
Overall
Females
Males
Variables
Adjusted OR (95% CI)
Adjusted OR (95% CI)
Adjusted OR (95% CI)
Sociodemographic variables
Age, y (Ref: 12-14)
15-17
3.62 (0.97-13.60)
4.03 (0.45-35.78)
7.89 (0.45-139.42)
Gender (Ref: Female)
Male
1.78 (1.00-3.16)
Race/Ethnicitya (Ref: Non-Hispanic White)
Non-Hispanic Black
0.50 (0.15-1.74)
0.32 (0.07-1.51)
0.91 (0.10-8.28)
Other
0.40 (0.17-0.94)
0.41 (0.10-1.38)
0.33 (0.11-0.97)
Hispanic
0.86 (0.45-1.65)
0.55 (0.22-1.38)
1.34 (0.39-4.61)
Tobacco-related variables
Age at first exposure to tobacco product (y)
(Ref: ≤14)
15-17
0.46 (0.16-1.33)
0.22 (0.03-1.39)
0.78 (0.12-5.17)
Advert appeal (Ref: No)
Yes
0.45 (0.18-1.06)
0.49 (0.15-1.58)
0.41 (0.07-2.35)
Substance use variables
Heavy drinking (Ref: No)
Yes
2.40 (1.39-4.16)
1.37 (0.62-2.99)
5.66 (1.67-19.18)
High-risk drinking (Ref: No)
Yes
1.75 (0.99-3.08)
1.82 (0.82-4.03)
1.57 (0.63-3.92)
Note: PATH = Population Assessment of Tobacco and Health, CI = confidence interval. Bold numbers represent P < 0.05. ¶Odds ratios were
calculated using multiple logistic regression and adjusted for survey weights and all variables. aOther indicates Non-Hispanic American Indian
or Alaska Native, Non-Hispanic Asian/Native Hawaiian or Other Pacific Islander and persons with multiple races
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Table 4 – Multivariable associations¶ for poly-tobacco use compared to mono-tobacco use among young adults (18-34
years) past 30days tobacco users overall, and stratified by gender: PATH Study, 2013-2014
Overall
Females
Males
Variables
Adjusted OR (95% CI)
Adjusted OR (95%
Adjusted OR (95%
CI)
CI)
Sociodemographic variables
Age, y (Ref: 25-34)
18-24
1.51 (1.13-2.02)
0.92 (0.57-1.51)
1.94 (1.40-2.70)
Gender (Ref: Female)
Male
1.42 (1.12-1.80)
Sexual Orientation (Ref: Heterosexual)
Lesbian, Gay, Bisexual, Other
1.26 (0.90-1.77)
1.62 (1.16-2.27)
0.63 (0.34-1.16)
Education (Ref: Bachelor’s or advanced degree)
Less than high school or GED
1.74 (1.22-2.49)
2.04 (1.08-3.88)
1.51 (0.96-2.38)
High school graduate
1.85 (1.33-2.57)
2.03 (1.07-3.83)
1.64 (1.07-2.53)
Some college or associate degree
1.39 (1.03-1.87)
1.43 (0.85-2.40)
1.32 (0.90-1.95)
Household income (Ref: $75,000)
<$25,000
1.24 (0.77-1.98)
1.34 (0.60-2.95)
1.32 (0.76-2.29)
$25,000-$74,999
1.31 (0.99-1.72)
1.32 (0.77-2.25)
1.32 (0.97-1.80)
Not reported
1.39 (1.03-1.87)
1.15 (0.65-2.02)
1.34 (0.97-1.86)
US census region (Ref: Northeast)
Midwest
1.32 (0.99-1.74)
1.09 (0.69-1.71)
1.53 (0.97-2.42)
South
1.75 (1.34-2.23)
1.72 (1.08-2.75)
1.84 (1.22-2.77)
West
1.24 (0.92-1.68)
1.27 (0.77-2.08)
1.28 (0.85-1.94)
Employment status (Ref: Full-time ≥35hours per
week
Part-time (15-24 hours per week)
0.82 (0.62-1.08)
0.82 (0.55-1.24)
0.78 (0.56-1.10)
Part-time (<15 hours per week)
0.96 (0.65-1.42)
0.78 (0.47-1.32)
1.11 (0.61-2.01)
Don’t currently work for pay
0.97 (0.77-1.23)
0.86 (0.60-1.24)
0.98 (0.71-1.37)
Self-perception of health (Ref: Fair/Poor)
Excellent
0.84 (0.57-1.24)
0.98 (0.53-1.79)
0.70 (0.41-1.21)
Very good
0.73 (0.51-1.04)
0.85 (0.52-1.41)
0.62 (0.38-1.03)
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Good
Tobacco-related variables
Age at first exposure to tobacco product (y) (Ref:2534)
<18
18-24
Preferred tobacco flavor (Ref: No)
Yes
Substance use variables
Heavy drinking (Ref: No)
Yes
High-risk drinking (Ref: No)
Yes
Marijuana use (Ref: >30days)
Within 30days

0.94 (0.66-1.32)

1.10 (0.67-1.81)

0.81 (0.50-1.31)

0.41 (0.26-0.66)
0.60 (0.44-0.83)

0.44 (0.20-0.94)
0.67 (0.37-1.20)

0.43 (0.24-0.75)
0.58 (0.41-0.82)

0.79 (0.65-0.96)

0.84 (0.56-1.24)

0.78 (0.63-0.95)

1.43 (1.17-1.74)

1.44 (1.05-1.97)

1.39 (1.08-1.81)

1.34 (1.09-1.66)

1.41 (0.95-2.08)

1.32 (1.03-1.69)

2.10 (1.75-2.51)

2.02 (1.46-2.79)

2.22 (1.74-2.84)

Note: PATH = Population Assessment of Tobacco and Health, CI = confidence interval. Bold numbers represent P < 0.05
¶
Odds ratios were calculated using multiple logistic regression and adjusted for survey weights and all variables
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Supplementary table 1 – Characteristics of Tobacco users among Youths (12-17 years): PATH Study, 2013-2014
Total, weighted %
Mono-tobacco use,
Poly-tobacco use,
P value
weighted % (95% CI)
weighted % (95% CI)
Total
1082 (100.0)
57.1 (53.9-60.2)
42.9 (39.8-46.1)
Sociodemographic variables
Age group (y)
0.0152
12-14
178 (15.4)
10.1 (8.5-12.1)
5.3 (4.1-6.9)
15-17
904 (84.6)
47.0 (43.9-50.0)
37.6 (34.6-40.7)
Gender
<0.0001
Male
588 (55.3)
27.6 (24.9-30.5)
27.7 (24.9-30.8)
Female
494 (44.7)
29.5 (26.6-32.6)
15.2 (13.1-17.5)
Sexual Orientation
0.2980
Heterosexual
880 (87.1)
48.5 (44.9-52.0)
38.6 (35.3-42.0)
Lesbian, Gay, Bisexual, Other
128 (12.9)
7.9 (6.1-10.2)
5.0 (3.7-6.8)
Race/Ethnicitya
0.0058
Non-Hispanic White
613 (63.1)
34.1 (30.0-37.4)
29.0 (26.0-32.2)
Non-Hispanic Black
116 (11.5)
8.2 (6.6-10.1)
3.3 (2.4-4.6)
Other
96 (7.0)
3.8 (2.8-5.2)
3.1 (2.3-4.4)
Hispanic
244 (18.4)
11.1 (9.3-13.1)
7.4 (5.9-9.1)
Grade in schoolb
0.1787
5-8
96 (8.6)
5.7 (4.4-7.2)
2.9 (2.0-4.2)
9-12
886 (86.0)
48.9 (45.8-52.0)
37.1 (34.0-40.3)
Other
61 (5.5)
3.1 (2.2-4.3)
2.4 (1.6-3.5)
Money received per week
0.1193
None
195 (18.1)
10.1 (8.5-12.1)
8.0 (6.3-10.1)
$10
214 (19.0)
12.3 (10.4-14.5)
6.7 (5.4-8.4)
$11-$50
381 (35.8)
19.4 (17.0-22.0)
16.4 (14.3-18.8)
>$50
286 (27.0)
15.1 (12.8-17.7)
11.9 (9.9-14.2)
US census region
0.7559
Northeast
186 (18.7)
10.5 (8.8-12.5)
8.1 (6.3-10.4)
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Midwest
South
West
Self-perception of overall
health
Excellent
Very good
Good
Fair/Poor
Tobacco-related variables
Age at first exposure to
tobacco product (y)
<14
15-17
Preferred tobacco flavor
Yes
No
Advert appeal
Yes
No
Substance use variables
Heavy drinkingc
Yes
No
High-risk drinkingd
Yes
No
Marijuana usee
Within the past 30days
>30days
Other substance usee
Within the past 30days

270 (23.9)
402 (37.4)
224 (20.0)

14.0 (12.0-16.2)
21.8 (18.7-25.3)
10.8 (8.7-13.3)

10.0 (8.1-12.2)
15.6 (13.5-17.8)
9.2 (7.4-11.5)
0.2382

491 (46.1)
380 (35.4)
162 (14.7)
46 (3.9)

26.5 (24.0-29.2)
21.3 (19.0-23.9)
7.5 (5.9-9.4)
2.0 (1.3-3.1)

19.6 (17.0-22.4)
14.1 (12.1-16.3)
7.2 (5.8-8.9)
1.8 (1.2-2.8)
0.0036

306 (26.7)
775 (73.3)

17.4 (15.2-19.9)
39.6 (36.4-43.0)

9.3 (7.5-11.4)
33.6 (30.7-36.7)

568 (67.6)
263 (32.4)

31.3 (28.1-34.8)
13.0 (10.8-15.7)

36.2 (33.0-39.6)
19.4 (16.7-22.4)

0.1650

0.0033
111 (12.4)
721 (87.6)

7.0 (5.4-8.9)
37.4 (34.1-40.9)

5.4 (4.1-7.2)
50.1 (46.7-53.6)
<0.0001

146 (36.4)
260 (63.6)

13.4 (10.4-17.1)
36.3 (31.6-41.3)

22.9 (18.8-22.7)
27.3 (23.1-32.0)

164 (42.7)
226 (57.3)

16.4 (12.4-21.2)
32.3 (27.5-37.6)

26.4 (21.9-31.4)
25.0 (20.7-29.8)

393 (56.2)
310 (43.8)

26.9 (23.6-30.5)
23.5 (20.5-26.9)

29.2 (25.6-33.1)
20.3 (17.3-23.6)

71 (23.8)

11.6 (8.3-16.0)

12.2 (8.9-16.4)

0.0017

0.1734

0.5612
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>30days

227 (76.2)

34.1 (28.6-40.1)

42.1 (36.1-48.3)

Note: PATH = Population Assessment of Tobacco and Health, CI = confidence interval. Unweighted sample size and weighted percentages are
presented; percentages are weighted to represent youth population. aOther refers to Non-Hispanic American Indian or Alaska Native, Non-Hispanic
Asian/Native Hawaiian or Other Pacific Islander and persons with multiple races. bOther refers to college, vocational/tech school, not enrolled,
homeschooled, ungraded (schools where students are not assigned to a particular grade). cAnswered by respondents who have ever used alcohol and
used alcohol in the past 30 days. dAnswered by respondents who have ever used alcohol, used in the past 30 days and drank on one or more days.
e
Answered by respondents who have ever used marijuana or other substance use (Ritalin, painkillers, cocaine, methamphetamine, and heroin).
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Supplementary table 2 – Characteristics of Tobacco users among Young Adults (18-34 years): PATH Study, 2013- 2014

Total
Sociodemographic variables
Age group (y)
18-24
25-34
Gender
Male
Female
Sexual Orientation
Heterosexual
Lesbian, Gay, Bisexual, Other
Race/Ethnicitya
Non-Hispanic White
Non-Hispanic Black
Other
Hispanic
Education
Less than high school or GED
High school graduate
Some college or associate’s degree
Bachelor’s degree or advanced
degree
Household incomeb
<$25,000
$25,000-$74,999
≥$75,000
Not reported
Employment status

Total,
weighted %
8377 (100.0)

Mono-tobacco use,
weighted % (95% CI)
52.1 (50.8-53.4)

Poly-tobacco use,
weighted % (95% CI)
47.9 (46.6-49.2)

4784 (44.7)
3591 (55.3)

20.5 (19.5-21.5)
31.6 (30.2-32.9)

24.2 (23.1-25.3)
23.7 (22.5-25.0)

4788 (60.4)
3589 (39.6)

28.4 (27.3-29.6)
23.7 (22.6-24.8)

32.0 (30.8-33.3)
15.8 (15.0-16.7)

7356 (90.1)
920 (9.9)

47.3 (45.9-48.7)
4.8 (4.3-5.4)

42.8 (41.5-44.1)
5.1 (4.4-5.7)

4818 (61.9)
1202 (13.3)
698 (7.5)
1596 (17.3)

32.1 (30.8-33.4)
6.8 (6.2-7.4)
3.7 (3.1-4.4)
9.5 (8.8-10.2)

29.8 (28.4-31.2)
6.5 (5.8-7.3)
3.8 (3.3-4.4)
7.9 (7.1-8.7)

P value

<0.0001

<0.0001

0.0479

0.2175

<0.0001
1924 (20.7)
2237 (26.5)
3279 (39.1)
937 (13.7)

10.5 (9.7-11.3)
13.5 (12.7-14.4)
20.0 (19.0-21.0)
8.2 (7.2-9.2)

10.2 (9.5-11.0)
13.0 (12.0-14.1)
19.1 (18.2-20.1)
5.5 (4.9-6.1)

4218 (46.5)
2500 (32.1)
997 (13.8)
662 (7.6)

23.0 (21.8-24.3)
17.3 (16.4-18.3)
7.8 (7.0-8.6)
4.0 (3.5-4.6)

23.5 (22.3-24.8)
14.7 (13.8-15.7)
6.0 (5.4-6.7)
3.6 (3.2-4.1)

0.0013

0.0098
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Full-time (≥35hours per week)
Part-time (15-24hours per week)
Part-time (<15hours per week)
Don’t currently work for pay
US census region
Northeast
Midwest
South
West
Self-perception of overall health
Excellent
Very good
Good
Fair/Poor
Tobacco-related variables
Age at first exposure to tobacco
product (y)
<18
18-24
25-34
Preferred tobacco flavor
Yes
No
Advert appeal
Yes
No
Substance use variables
Heavy drinkingc
Yes
No
High-risk drinkingd
Yes

3751 (49.4)
1542 (17.2)
530 (5.9)
2498 (27.4)

26.7 (25.3-28.2)
8.4 (7.7-9.2)
2.8 (2.5-3.3)
14.1 (13.0-15.2)

22.6 (21.5-23.8)
8.8 (8.2-9.5)
3.1 (2.7-3.5)
13.4 (12.6-14.2)

1278 (17.5)
2049 (22.2)
3305 (39.3)
1745 (20.9)

10.1 (9.1-11.2)
11.6 (10.7-12.6)
19.9 (18.6-21.2)
10.5 (9.4-11.7)

7.4 (6.6-8.3)
10.6 (9.6-11.6)
19.5 (18.1-20.9)
10.4 (9.2-11.8)

1297 (15.5)
2780 (33.8)
3209 (38.2)
1077 (12.4)

8.4 (7.7- 9.1)
18.0 (17.1-19.0)
19.3 (18.2-20.4)
6.4 (5.8-7.2)

7.1 (6.6-7.7)
15.8 (14.8-16.7)
19.0 (18.1-19.9)
6.0 (5.5-6.5)

0.0008

0.0894

0.0017
816 (9.2)
4835 (54.6)
2202 (36.2)

5.1 (4.6-5.7)
25.7 (24.7-26.8)
17.9 (16.8-19.0)

4.1 (3.7-4.6)
28.8 (27.6-30.1)
18.3 (17.2-19.4)

3509 (62.0)
2075 (38.0)

23.3 (21.9-24.7)
12.1 (11.1-13.1)

38.7 (37.0-40.4)
26.0 (24.6-27.3)

438 (7.6)
5147 (92.4)

2.8 (2.3-3.3)
32.6 (31.1-34.1)

4.8 (4.3-5.5)
59.8 (58.3-61.2)

0.0004

0.6104

<0.0001
3057 (58.1)
2351 (41.9)

27.0 (25.6-28.4)
22.7 (21.4-24.0)

31.1 (29.7-32.6)
19.1 (18.1-20.2)

3558 (67.0)

34.8 (33.3-36.2)

32.3 (31.0-33.5)

<0.0001
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No
Marijuana usee
Within the past 30days
>30days
Other substance usee
Within the past 30days
>30days

1808 (33.0)

14.9 (13.9-16.0)

18.0 (16.9-19.2)
<0.0001

2454 (40.9)
3240 (59.1)

14.7 (13.7-15.8)
31.9 (30.4-33.4)

26.2 (24.9-27.4)
27.2 (25.7-28.7)

317 (9.8)
2840 (90.2)

4.3 (3.5 – 5.4)
40.6 (38.4 – 42.7)

5.5 (4.8 – 6.4)
49.6 (47.6 – 51.6)

0.7874

Note: PATH = Population Assessment of Tobacco and Health, CI = confidence interval. Unweighted sample size and weighted percentages are
presented.
a
Black persons and young adults (18–24) were oversampled; percentages are weighted to represent young adult populations; Other refers to NonHispanic American Indian or Alaska Native, Non-Hispanic Asian/Native Hawaiian or Other Pacific Islander and persons with multiple races.
b
Household income includes those who refused to report their income. cAnswered by respondents who have ever used alcohol and used alcohol
in the past 30 days. dAnswered by respondents who have ever used alcohol, used in the past 30 days and drank on one or more days. eAnswered
by respondents who have ever used marijuana or other substance use (Ritalin, painkillers, cocaine, methamphetamine, and heroin)
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© Copyright 2019
E-cigarette trajectories among US youth and adults; results from the Population
Assessment of Tobacco and Health Study Waves 1,2,3 (2013-2016)
Abstract
Background: The dramatic increase of e-cigarette use among youth in the US has prompted
regulatory action to address their spread.
Objective: To address the relative scale of key potentially positive and negative transitions of ecigarettes in the US over a period of 2 years including; for youth 1- trends in e-cigarette uptake
among never cigarette smokers; 2) transition from e-cigarette mono use to cigarette smoking; and
for adults 3) transition of dual (e-cigarette/cigarette) use to mono or no tobacco use (quitting).
Design: Analysis of longitudinal data from representative population-based samples of US youth
(12-17 years) and adults (≥18 years) from Waves 1-3 of the Population Assessment of Tobacco
and Health (PATH) Study.
Setting: PATH Wave 1 was conducted between 2013-2014 (13,621 youth, 32,320 adults); Wave
2 between 2014-2015 (12,172 youth, 28,362 adults); and Wave 3 between 2015-2016 (11,814
youth, 28,148 adults).
Participants: Participants were obtained from Waves 1-3 of PATH for US youth and adults.
Measurements: Weighted prevalence estimates of self-reported current (past 30 days) ecigarette use and cigarette smoking among youth and adults in Waves 1-3.
Results: Between 2013-2016, e-cigarette use in the US increased among youth but not adults.
Young e-cigarette users were more likely to be never cigarette smokers compared to older ones.
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Youth results show that among e-cigarette users at each wave the proportion of never cigarette
smokers rose from 24.1% in Wave 1 to 42.6% in Wave 3 (p=0.0001 for trends). Of youth ecigarette mono users in Wave 1, 34.4% transitioned to cigarette smoking (10.9% mono cigarette,
23.5% dual use) at Wave 3, compared to 45.3% reporting no tobacco use, and 20.3% reporting ecigarette mono use.
Adult results show that for e-cigarette dual users in Wave 1, 8.8% transitioned to no tobacco use
at Wave 3, 6.2% continued as mono e-cigarette users, while 85% either relapsed to cigarettes
(53.5%) or continued dual use (31.5%). Among adult e-cigarette users who never smoked
cigarettes at Wave 1, 25% transitioned to cigarette smoking in Wave 3.
Limitation: The question about current e-cigarette use was changed in Wave 3 to include past 30
days use of any ENDS including (e-cigarettes, e-cigars, e-hookahs, e-pipes, hookah pens,
personal vaporizers, and vape pens).
Conclusions: In both young and adult current e-cigarette users, there was more relapse, dual-use,
and transition to cigarette smoking, as well as e-cigarette uptake among young never cigarette
smokers than quitting among adult smokers. This imbalance in the scale of potentially positive
and negative transitions related to e-cigarettes in the society needs to be considered carefully
when planning regulatory actions for e-cigarettes.
Keywords: Cigarettes, E-cigarettes, Dual use, Harm reduction, Youth, Adults, US, Population,
Longitudinal
Introduction
The recent evidence of the dramatic increase of e-cigarette (a.k.a. electronic nicotine
delivery systems, ENDS) use among youth in the US has intensified the debate about their
possible contribution to reducing harm from tobacco use in the society, as well as concerns about
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their potential role in smoking uptake (US Department of Health and Human Services 2016;
NASEM 2018). Reports based on the National Youth Tobacco Survey (NYTS) show a 78%
increase in e-cigarette use among high school students in 2018 alone. At the same time, sales of
Juul e-cigarettes that are particularly popular among youth rose 641% to dominate the market
share of this product (Cullen et al., 2018; King et al., 2018).
A central premise of e-cigarette harm reduction is that, should their use continue to
proliferate, they will reduce smoking harms throughout whole populations by enabling cessation
and reducing smoking frequency. From this perspective, the potential of e-cigarettes for tobacco
control promises an unprecedented reduction in the global burden of disease caused by smoking
(Abrams et al., 2018; McNeill et al., 2015; Hajek et al., 2014). These forecasts are based on
expectations that the net contribution of e-cigarette use across whole populations will be positive,
meaning that the numbers of smokers who quit smoking via e-cigarettes will be larger than the
combined numbers of those who relapse back to smoking, keep both smoking and e-cigarettes use
(dual users), and previous nonsmokers who commence smoking after first using e-cigarettes
(Warner & Mendez 2018). On the other hand, the increased popularity of e-cigarettes among
youth, and their potential to lead to cigarette smoking are raising concerns about their role in
expanding the nicotine addiction base among young people and subsequent perpetuation of the
tobacco epidemic (Glantz & Bareham 2018; Soneji et al., 2017; Chapman et al., 2018).
The debate on the impact of e-cigarettes in populations has often been marred by
inferring causal or population effects from cross-sectional, ecological or data obtained from
limited samples or short follow-ups (Barrington-Trimis et al., 2015; Dutra & Glantz 2014; US
Department of Health and Human Services 2018). The 2018 report on e-cigarettes by the
National Academies of Science, Engineering and Medicine (NASEM) emphasized that because
the e-cigarette phenomenon is relatively recent, “the majority of studies … lack sufficient
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duration of follow-up to study the naturalistic cigarette smoking progression sequence”(NASEM
2018). Accordingly, what has been missing is a real-world look at the totality of potentially
positive and negative transitions of e-cigarette use in the US, based on representative longitudinal
data with sufficient follow up.
In 2011, the NIH and FDA commenced the Population Assessment of Tobacco and
Health cohort study (PATH), as the first large research effort since Congress gave FDA the
authority to regulate tobacco products in 2009 (US Department of Health and Human Services
2018; Hyland et al., 2017). Studies from PATH Waves 1, and 2 started answering some of the
important questions about e-cigarette transition during a 1-year period among US adults
(Coleman et al., 2018; Verplaeste et al., 2018). So far, these studies have shown mixed results
about the value of e-cigarettes for adult cigarette smokers’ cessation. For example, Coleman and
colleagues found that the majority of adult dual users in Wave 1 (87.8%) either continued dualuse or relapsed to cigarette-only smoking at one year follow up, compared to 12.1% who quit
cigarette smoking (Coleman et al., 2018). With the recent availability of Wave 3 data from PATH
(October 2018), we have the opportunity to look at an extended follow-up of 2 years and use such
data to assess additionally youth uptake of e-cigarettes and its relation to cigarette smoking.
In this analysis, we consider three waves of PATH data for youth and adults, to provide a
comparative overview of the real-world evolution of e-cigarette use in relation to cigarette
smoking in the US between 2013-2016. Currently, the debate surrounding the regulation of ecigarettes focuses mostly on the size of e-cigarettes’ potentially beneficial effects to the society
(e.g., adult cessation) vs. their unwarranted effects (e.g., uptake among tobacco naïve
adolescents) (Abrams et al., 2018). Therefore, we aimed in this study to answer 3 questions that
reflect these outcomes based on the relative scale of key potentially positive and negative
transitions of e-cigarettes in the US over a period of 2 years including; for youth 1- trends in e-
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cigarette uptake among never cigarette smokers; 2) transition from e-cigarette mono use to
cigarette smoking; and for adults 3) transition of dual (e-cigarette/cigarette) use to mono or no
tobacco use (quitting). While our assessment does not imply a direct measurement of
harm/benefit differentials between these transitions, it provides what much of the policy and
regulatory debate around e-cigarettes have focused on; the relative scale of these transitions in a
real-world setting (2, 5).
Methods
Study Sample and Overview
Data from Waves 1 (2013-2014), 2 (2014-2015) and 3 (2015-2016) of the PATH Study
were used in this analysis. The detailed methodology for the PATH Study has been previously
described (15). Briefly, the PATH study is a nationally representative sample of 45,971 youth and
adults aged ≥12years old. Youth (12-17 years) and adults (≥18 years) were sampled separately
using audio computer-assisted self-interview (ACASI), available in English and Spanish. The
PATH study employs a multistage sampling design to produce a nationally representative sample
of the US population. Adult tobacco users, young adults (aged 18–24 years), and AfricanAmericans were oversampled to make results nationally representative of the general population
(US Department of Health and Human Services, 2018). The overall response rate at Wave 1 was
78.4% for youth and 74.0% for adults yielding a total of 13,621 youth and 32,320 adult
participants. At Wave 2, the response rate was 87.3% for youth and 83.2% for adults yielding a
total of 12,172 youth and 28,362 adult participants. At Wave 3, the response rate was 83.3% for
youth and 78.4% for adults yielding a total of 11,814 youth and 28,148 adult participants. In this
study, our analysis focused on youth and adults who report current use (past 30 days) of ecigarettes, alone or in combination with cigarettes (dual use) at Wave 1 and had complete followup information at Wave 3 to look at important transitions within 2 years. Survey responses were
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weighted to adjust for nonresponse, varying selection probabilities, and oversampling to reflect
national demographics (US Department of Health and Human Services, 2018). The Institutional
Review Board of Florida International University approved the study and deemed it exempt.
Study Measures
Tobacco products use:
Current e-cigarette use was derived from the answers to two questions about; “ever used
an e-cigarette” and respondents who answered “yes” were asked; “used an e-cigarette at least
once in the past 30 days” for both youth and adults at each wave (Kasza et al., 2017; Chaffee et
al., 2018; Dai et al., 2018). This definition was also applied to current cigarette smoking. Ever
cigarette smoking was assessed with the question about; “(n)ever smoked a cigarette, even one or
two puffs” for youth and adults (Chaffee et al., 2018). Positive and negative responses to this
question defined the ever and never cigarette smoking categories used in our analysis. As ecigarette/cigarette is the most common and important combination for the regulatory implications
of e-cigarettes (Kasza et al., 2017), dual use was derived from positive responses to both current
e-cigarette and cigarette use. To broaden the representativeness of our analysis, given that polytobacco is becoming common among US youth (Osibogun et al., 2018), dual users who reported
the use of other tobacco products were still counted towards the dual use category. In Wave 3,
the e-cigarette use question was expanded to include other electronic nicotine delivery systems
(ENDs, including e-cigarettes, e-cigars, e-hookahs, e-pipes, hookah pens, personal vaporizers,
and vape pens), with current use implying the use of any ENDS in the past 30 days (US
Department of Health and Human Services, 2018). To avoid confusion and have consistent
terminology, we have used the term e-cigarettes throughout and pointed to the possible effect of
the change in the e-cigarette question in Wave 3 on our analysis in the limitations section.
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Transitions
All studied transitions are for current (past 30 days) tobacco use status. The change in the
status of e-cigarette use between Waves 1 to 3 was considered for regulatory-important
transitions for both e-cigarette mono and dual users (Coleman et al., 2018). For current e-cigarette
mono users at Wave 1, we considered the following transitions between Waves 1 and 3; 1)
transition to dual use, 2) continuing with e-cigarette mono use, 3) transition to cigarette mono use
and 4) transition to no use of any tobacco product (quitting). For current dual users at Wave 1 we
considered the following transitions between Waves 1 and 3; 1) continuing with dual use, 2)
transition to e-cigarette mono use, 3) relapse to cigarette mono use, 4) transition to no use of any
tobacco product (considered as an indicator of quitting).
Statistical analyses
We used summaries of weighted prevalence estimates of participants with complete data
for current e-cigarette use and cigarette smoking status in the overall population in the 3 Waves
separately for both youth and adults. Next, we summarized the age-group distribution of current
e-cigarette use by ever cigarette smoking status for youth and adults in the 3 Waves. Furthermore,
we calculated the prevalence estimates for e-cigarette mono and dual users among youth and
adults identified from Wave 1 and assessed the change in their use status at Wave 3 (Coleman et
al., 2018).
The replicate weights provided by the PATH Study for the three Waves were used to
obtain unbiased variance estimates using Fay's Method of Balanced Repeated Replication, with
the Fay coefficient value of 0.3, as recommended by the PATH Study team (US Department of
Health and Human Services, 2018). Weighted percentages were reported with their corresponding
95% confidence intervals (CI). Pearson chi-square tests were used to evaluate differences in
proportions between ever cigarette and never cigarette smoking by e-cigarette use status for youth
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and adults. We tested the linear trend for the proportions of overall current e-cigarette use, ecigarette use by ever and never cigarette smoking against the general population of the PATH
study, and across the 3 Waves using the chi-square test for trends. We also evaluated the
differences between identified transitions among youth and adult e-cigarette users using the
Pearson chi-square test. All data analyses were performed using STATA 14.2 (Stata Corp,
College Station, TX) and a P value of <0.05 was considered statistically significant.
Role of the Funding Source
Dr. Osibogun is supported by the Dissertation Year Fellowship from Florida International
University (FIU) during the time of conducting this study. However, FIU had no role in the study
design, analysis or interpretation of the data; preparation, review or approval of the manuscript, or
the decision to submit the manuscript for publication. Dr. Maziak is supported by NIH grants
R01-DA035160, R01-TW010654, R01-DA042477, and U54MD012393-01 for the FIU-RCMI.
Results
Overall e-cigarette prevalence and trends among youth and adults
The overall prevalence of current (past 30 days) e-cigarette use among 13,559 youth in
Wave 1 was 3.1% (95% CI: 2.8-3.5), increasing to 3.6% (95% CI: 3.2-4.1) in Wave 2 among
12,059 youth, and 4.1% (95% CI: 3.7-4.7) in Wave 3 among 11,546 youth (P=0.0008 for trends)
(Table 1). Among 32,222 US adults in Wave 1, the overall prevalence of current (past 30 days) ecigarette use was 6.7% (95% CI: 6.4-7.0), becoming 6.3% (95% CI: 5.9-6.6) in Wave 2 among
27,458 adults, and 7.0% (95% CI: 6.7-7.3) in Wave 3 among 27,860 adults (P =0.44 for trends)
(Table 2). Below we provide study results according to our study’s three main objectives.
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1- Trends of e-cigarette uptake among youth never smokers (2013-2016)

In Wave 1, 24.1% (95% CI: 20.1-28.6) of current e-cigarette users were never cigarette
smokers, increasing to 35.8% (95% CI: 31.1-40.7) in Wave 2, and 38.2% (95% CI: 32.8-43.9) in
Wave 3 (P=0.0003 for trends; data not shown). Since the profile of young e-cigarette smokers is
likely to change with time, we compared newly reported e-cigarette smokers at each wave (i.e.,
did not report e-cigarette use in the previous wave) and found that the proportion of never
smokers among new e-cigarette users rose from 24.1% in Wave 1 to 42.6% in Wave 3 (P=0.0001
for trends; Figure 1).
2- E-cigarette transitions among US youth (2013-2016)
For e-cigarette mono users in Wave 1 (n=167), 34.4% transitioned to cigarette smoking
(10.9% mono cigarette, 23.5% dual use) at Wave 3, compared to 65.6% reporting no tobacco use
(45.3%), or e-cigarette mono use at Wave 3 (20.3%) (p<0.0001; Table 3). This trend differed
according to ever cigarette smoking status, whereby among e-cigarette users, never cigarette
smokers in Wave 1, 19.9% transitioned to cigarette smoking (7.2% cigarette, 12.7% dual use) at
Wave 3, compared to 61.4% transitioning to cigarette smoking (24.5% cigarette, 39.7% dual use)
among e-cigarette, ever cigarette smokers (p<0.005; Figure 2).
Among youth dual users in Wave 1 (n=153), 73.9% transitioned to either cigarette
smoking or dual use in Wave 3, thus can be considered to have been held in smoking 24 months
later compared to 26.1% who have potentially benefitted from e-cigarettes by transitioning to ecigarette mono use or no use of any tobacco product (quitting) (Table 3).
3- Dual use transitions among US adults (2013-2016)
In Wave 1, 2.3% (95% CI: 1.9-2.9) of adult current e-cigarette users were never cigarette
smokers, increasing to 2.8% (95% CI: 2.3-3.5) in Wave 2, and 6.5% (95% CI: 5.7-7.5) in Wave 3
(P<0.0001 for trends; data not shown).
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For adult dual users in Wave 1 (n=2631), 53.5% relapsed to mono cigarette smoking in
Wave 3, and 31.5% continued as dual users. Thus, 85% of adult dual users can be considered to
have been held in smoking (dual use or relapse to cigarette smoking) 24 months later compared to
15% who have potentially benefitted from e-cigarettes by transitioning to e-cigarette mono use or
no use of any tobacco product (quitting). For adult e-cigarette mono users at Wave 1 (n=608),
37.6% reported no current use of any tobacco product at Wave 3, compared to 62.4% who either
continued with e-cigarettes (49.7%) or progressed to cigarette smoking (12.7%) (details in Table
4).
Discussion
Our analysis of PATH’s three waves provides a comprehensive perspective of the
evolution of e-cigarette use among youth and adults in the US between 2013-2016. Overall, the
study shows that e-cigarette use is increasing among youth but not adults and that younger ecigarette users are becoming more likely to be never than ever cigarette smokers. Adult ecigarette users, by contrast, were mostly cigarette smokers. Looking at e-cigarette transition to
cigarette smoking in youth shows that one out of five e-cigarette users, never cigarette smokers in
Wave 1 transitioned to cigarette smoking at Wave 3. E-cigarettes transitions in adults show that
among dual users in Wave 1, 15% became current nonsmokers, while 85% either relapsed to
cigarette smoking (53.5%) or continued as dual users (31.5%) at Wave 3. Below we discuss our
results briefly according to the three key questions addressing the relative scale of e-cigarette
potentially beneficial vs. harmful transitions among youth and adults in the US between 20132016.
Trends of e-cigarette uptake among youth never smokers (2013-2016)
One of the main criteria to judge e-cigarettes’ potential for harm-reduction is their utility
in helping adult smokers quit, but without causing substantial initiation and addiction among
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young never smokers (Maziak 2014). This youth initiation question is acquiring increasing
importance as evidence of young e-cigarette smokers being at greater risk of progressing to
cigarette smoking compared to non-e-cigarette users are accumulating (Soneji et al., 2017; East et
al., 2018). Our analysis offers a dynamic perspective of young e-cigarette users’ profile in the US,
whereby they are increasingly more likely to be those who have never smoked cigarettes. As
Figure 1 shows, the proportion of never cigarette smokers among young e-cigarette users almost
doubled between Waves 1-3 (from 24.1% to 42.6%). This finding contrasts with data from other
countries showing a limited scope of e-cigarette uptake among youth never cigarette smokers
(Use of e-cigarettes, Great Britain 2014). Thus, in the US e-cigarettes are increasingly attracting
cigarette naïve adolescents, who are most vulnerable to the effect of nicotine on their developing
brain (NASEM 2018, Barrington-Trimis & Leventhal 2018), and the consequences of lifelong
nicotine addiction (US Department of Health and Human Services, 2012).
E-cigarette transitions among US youth (2013-2016)
E-cigarettes’ potential to lead to cigarette smoking is another important outcome for
judging their unwanted effects as a means of harm reduction, especially in youth (Chapman et al.,
2018, Chapman 2013). Such potential can be assessed in our analysis by looking at the trajectory
of e-cigarette mono use among youth between Waves 1 and 3. This analysis shows that for every
adolescent e-cigarette mono user in Wave 1 who became non-tobacco user (quit) in Wave 3, there
was one who became a cigarette smoker or dual user. This may not provide a firm answer to the
debate about whether young e-cigarette users are predisposed to tobacco/nicotine experimentation
rather than at increased risk of smoking because of their e-cigarette use (Barrington-Trimis et al.,
2016; Primack et al., 2015; Etter 2018). Of special interest for such debate is the evolution of ecigarette users who have never tried cigarettes before, since this can represent most closely ecigarettes’ potential in a real-world setting to recruit youth to cigarette smoking. Our analysis
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shows that amongst cigarette naïve youth, about one out of five current e-cigarette only users end
up being current cigarette smokers two years later, signaling the importance of e-cigarettes’
potential to lead to cigarette smoking.
Dual use transitions among US adults (2013-2016)
The potential of e-cigarettes to aid smoking cessation at the population level has focused
mostly on whether dual use in adults is a transitional stage towards cigarette quitting or an
emerging tobacco use pattern with a distinctive profile (Rahman et al., 2015). Looking at the
totality of dual-use trajectories between 2013-2016, our analysis shows that for every one adult
who quits cigarette smoking with the help of e-cigarettes there were about 3.6 who relapsed to
cigarette smoking, and two continuing as dual users. While smoking cessation methods used in
real-world conditions have varying short and long-term effectiveness, claims of e-cigarette
superiority in such setting are repeatedly made (Benmarhnia et al., 2018; Bullen et al., 2013;
Caponnetto et al., 2013; Tseng et al., 2016). Benmarhnia et al.’s analysis of transitions between
Waves 1 and 2 in the PATH data show that 5.6% of e-cigarette users at Wave 1 were persistently
abstinent from all tobacco products at Wave 2 (32). This is compared with rates of 6.1% for
(NRT), 10.2% for (varenicline), 10.3% for (bupropion) and 12.5% for (no aid used) (Benmarhnia
et al., 2018).
Limitations
Our study’s main limitation is that between waves, changes were made to the PATH
study questionnaire. Specifically, in Wave 3 the questions about e-cigarette use were replaced by
a more generic question about the use of any ENDS (including e-cigarettes, e-cigars, e-hookahs,
e-pipes, hookah pens, personal vaporizers, and vape pens). However, this is unlikely to have
affected our analysis substantially as we focused on the trajectory of e-cigarette users at Wave 1
(baseline) in subsequent waves and having an expanded definition of e-cigarette in Wave 3 will
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not affect our classification of outcomes. Moreover, we focused our analysis on ecigarette/cigarette interaction without entertaining other tobacco products combinations in the US
(Kasza et al., 2017), since this is the primary interaction shaping the discourse about e-cigarettes’
potential to affect morbidity and mortality of cigarettes smoking (NASEM 2018). Finally, we
considered only transitions in current use between Waves 1-3, which may not represent prolonged
use patterns (e.g., longer no tobacco use is usually needed to establish quitting). However, our
main aim in this study is to provide a real-world descriptive picture of common e-cigarette
trajectories and their relative scale rather than address the complex nuances of each of those
outcomes.
Conclusions
The comprehensive picture from 3 waves of the PATH about tobacco use evolution
among US youth and adults offers a cause for concern for the balance between e-cigarettes
beneficial and negative potentials. In both young and adult e-cigarette users, we see more relapse,
dual-use, and transition to cigarette smoking, as well as potentially spreading of nicotine
addiction among young never-smokers than quitting among adult smokers. While our assessment
does not imply a direct measurement of harm differentials between these key e-cigarette
transitions, it provides what much of the policy and regulatory debate around e-cigarettes have
focused on; their relative scale in a real-world population setting. Accordingly, the imbalance in
the scale of potentially positive and negative transitions related to e-cigarettes in the US needs to
be considered carefully when planning regulatory actions for e-cigarettes.
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Table 1: Prevalence of current e-cigarette use among US youth (12-17years) by cigarette smoking history:
PATH Cohort Study 2013-2016
Current E-cigarette use
Ever Cigarette use, n (%,
Never Cigarette use, n (%, 95%
Total, n (%, 95% CI)
95% CI)
CI)
Wave 1; 2013-2014 (N=13,559)
Yes, n (%, 95% CI)
321 (2.4, 2.1-2.7)*
418 (3.1, 2.8-3.5) ||
97 (0.8, 0.6-0.9)‡, §
Age, n (%, 95% CI)
12-14
50 (64.7, 53.6-74.5)†
26 (35.3, 25.5-46.4)
76 (100.0)
15-17
271 (78.1, 72.8-82.5)
71 (21.9, 175-27.2)
342 (100.0)
Wave 2; 2014-2015 (N=12,059)
Yes, n (%, 95% CI)
273 (2.3, 2.0-2.7)
141 (1.3, 1.1-1.6)
414 (3.6, 3.2-4.1)
Age, n (%, 95% CI)
12-14
53 (60.5, 47.8-71.9)
35 (39.5, 28.1-32.3)
88 (100.0)
15-17
220 (65.2, 60.0-70.3)
106 (34.8, 29.7-40.3)
326 (100.0)
Wave 3; 2015-2016 (N=11,546)
Yes, n (%, 95% CI)
273 (2.5, 2.2-3.0)
176 (1.6, 1.3-1.9)
449 (4.1, 3.7-4.7)
Age, n (%, 95% CI)
12-14
50 (53.5, 42.4-64.4)
39 (46.5, 35.6-57.6)
89 (100.0)
15-17
223 (63.6, 57.3-69.5)
137 (36.4, 30.5-42.7)
360 (100.0)
Abbreviations: PATH, Population Assessment of Tobacco and Health Study; n, unweighted sample; %, weighted percentages rounded up to 1
decimal place; CI, confidence interval.
*
Indicates significant (p<0.05) difference between ever and never cigarette smoking among e-cigarette users at each wave
†
Indicates significant (p<0.05) difference between age-groups for ever and never cigarette smoking among e-cigarette users at Wave 1 only
‡
Indicates significant (p<0.05) linear trend for the comparison across Waves 1-3 for the proportion of overall e-cigarette never cigarette users
among all study participants
§
Indicates significant (p<0.05) linear trend for the comparison across Waves 1-3 for the proportion of overall never cigarette use among current
e-cigarette users
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||

Indicates significant (p<0.05) linear trend for the comparison across Waves 1-3 for the proportion of overall e-cigarette use among all study
participants
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Table 2: Prevalence of current e-cigarette use among US adults (≥18 years) by cigarette smoking history:
PATH Cohort Study, 2013-2016
Current E-cigarette use Ever Cigarette use, n (%, 95% CI) Never Cigarette use, n (%, 95% CI)
Total, n (%, 95% CI)
Wave 1; 2013-2014 (N=32,222)
Yes, n (%, 95% CI)
4308 (6.5, 6.2-6.8)*, ‡
119 (0.2, 0.1-0.2)§, ||
4427 (6.7, 6.4-7.0)
Age, n (%, 95% CI)
18-24
1420 (93.3, 91.5-94.7)†
94 (6.7, 5.3-8.5)
1514 (100.0)
25+
2888 (99.1, 98.6-99.4)
25 (0.9, 0.6-1.4)
2913 (100.0)
Wave 2; 2014-2015 (N=27,458)
Yes, n (%, 95% CI)
3262 (6.1, 5.8-6.5)
117 (0.2, 0.1-0.2)
3379 (6.3, 5.9-6.6)
Age, n (%, 95% CI)
18-24
1071 (90.0, 87.3-92.0)
109 (10.1, 8.0-12.7)
1180 (100.0)
25+
2191 (99.6, 99.1-99.8)
8 (0.4, 0.2-1.0)
2217 (100.0)
Wave 3; 2015-2016 (N=27,860)
Yes, n (%, 95% CI)
3478 (6.6, 6.3-6.9)
298 (0.5, 0.4-0.5)
3776 (7.0, 6.7-7.3)
Age, n (%, 95% CI)
18-24
1347 (82.8, 80.4-84.9)
268 (17.2, 15.1-19.6)
1615 (100.0)
25+
2131 (98.2, 97.1-98.9)
30 (1.8, 1.1-2.9)
2161 (100.0)
Abbreviation: PATH, Population Assessment of Tobacco and Health Study; n, unweighted sample, %, weighted percentages rounded up to 1
decimal place; CI, confidence interval.
* Indicates significant (p<0.05) difference between ever and never cigarette smoking among e-cigarette users at each wave
†
Indicates significant (p<0.05) difference between age-groups for ever and never cigarette smoking among e-cigarette users at each wave
‡
Indicates significant (p<0.05) linear trend for the comparison across Waves 1-3 for the proportion of overall e-cigarette ever cigarette users
among all study participants
§
Indicates significant (p<0.05) linear trend for the comparison across Waves 1-3 for the proportion of overall e-cigarette never cigarette users
among all study participants
||
Indicates significant (p<0.05) linear trend for the comparison across Waves 1-3 for the proportion of overall never cigarette users among current ecigarette users
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Table 3: Transition of current e-cigarette use among US youth (12-17 years) between Waves 1 and 3 of PATH Cohort Study,
2013-2016
Wave 3
E-cigarette dual use
E-cigarette mono use Cigarette mono use No tobacco use
Wave 1
n (%, 95% CI)
n (%, 95% CI)
n (%, 95% CI)
n (%, 95% CI)
Total (n=320)

103 (32.5, 27.3-38.3)

47 (15.7, 12.3-19.8)

69 (19.9, 15.8-24.8)

E-cigarette dual use (n=153)

65 (43.3, 34.5-52.6)

14 (10.1, 5.6-17.7)

49 (30.6, 23.4-38.9)

E-cigarette mono use (n=167)

38 (23.5, 17.2-31.2)

33 (20.3, 15.2-26.6)

20 (10.9, 7.4-15.8)

101 (31.9, 26.937.4)*
25 (16.0, 10.922.9)
76 (45.3, 37.453.5)

Abbreviations: PATH, Population Assessment of Tobacco and Health; %, weighted percentage; 95% CI, 95% confidence interval.
Note: Frequencies are unweighted; weighted % are row %
*Indicates differences between groups (e-cigarette dual use, e-cigarette mono use, cigarette mono use and no tobacco use) were significant at p
<0.0001.
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Table 4: Transition of current e-cigarette use among US adults (≥18 years) between Waves 1 and 3 of PATH Cohort Study, 20132016
Wave 3
E-cigarette dual use
E-cigarette mono use
Cigarette mono use
No tobacco use
Wave 1
n (%, 95% CI)
n (%, 95% CI)
n (%, 95% CI)
n (%, 95% CI)
Total (n=3239)

924 (27.9, 26.0-29.8)

363 (12.1, 10.5-13.8)

1487 (45.8, 43.8-47.9)

E-cigarette dual use (n=2631)

839 (31.5, 29.4-33.7)

152 (6.2, 5.1-7.6)

1405 (53.5, 51.2-55.9)

E-cigarette mono use (n=608)

85 (12.3, 9.7-15.3)

211 (37.4, 32.9-42.2)

82 (12.7, 10.4-15.4)

465 (14.2, 12.915.6)*
235 (8.8, 7.79.9)
230 (37.6, 33.442.1)

Abbreviations: PATH, Population Assessment of Tobacco and Health; %, weighted percentage; 95% CI, 95% confidence interval.
Note: Frequencies are unweighted; weighted % are row %.
* Indicates differences between groups (e-cigarette dual use, e-cigarette mono use, cigarette mono use and no tobacco use) were significant at p <0.0001.
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Note: %, percentages rounded up to 1 decimal place; PATH indicates Population Assessment of Tobacco
and Health;
*
Indicates significant (p<0.005) linear trends across Waves 1-3 for never cigarette use among current ecigarette users
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Note: %, percentages rounded up to 1 decimal place; PATH indicates Population Assessment of Tobacco
and Health; * Indicates significant (p<0.05) difference between dual use at Wave 3 among e-cigarette never
cigarette users and e-cigarette ever cigarette users; * Indicates significant (p<0.0001) difference between
cigarette smoking at Wave 3 among e-cigarette never cigarette users and e-cigarette ever cigarette users; *
Indicates significant (p<0.0001) difference between no tobacco use at Wave 3 among e-cigarette never
cigarette users and e-cigarette ever cigarette users.
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Can e-cigarettes help adult smokers who cannot quit? Results from The Population
Assessment of Tobacco and Health Study Waves 1,2,3 (2013-2016)
Abstract
Background: We examined the trajectory followed by US adults who are dual ecigarette/cigarette users over two years in relation to nicotine dependence (ND) symptoms,
interest in quitting, and history of clinical cardiovascular disease (CVD).
Methods: We used data from the Population Assessment of Tobacco and Health Study (PATH)
Waves 1-3 (2013-2016). Adults (≥18years) who reported past 30 days use of both e-cigarettes
and cigarettes were identified from Wave 1 and followed for important tobacco use transitions
(cessation, harm reduction, and relapse) at two-year follow up (Wave 3). Multinomial logistic
regression models were conducted to examine the associations between these transitions and ND
symptoms, interest in quitting, and history of CVD.
Findings: Among 1,870 adult dual tobacco users at Wave 1, 25·8% (95% CI 23·5-28·3) were
still dual users 2 years later (Wave 3), 11·9% (95% CI 10·5-13·5) reported no current tobacco use
(cessation transition), 7·0% (95% CI 5·5-8·7) reported e-cigarette mono use (harm reduction
transition), and 55·3% (95% CI 52·6-58·0) reported cigarette mono use (relapse transition). In the
multivariate regression analysis, greater ND severity was associated with lower odds of following
cessation (OR 0·36; 95%CI 0·15-0·88) and harm reduction (OR 0·18; 95% CI 0·04-0·82)
transitions. Interest in quitting and clinical CVD factors were not associated with cessation or
harm reduction transitions.
Interpretation: Based on population data with prolonged follow up, e-cigarettes do not seem to
offer an advantage for adults who need to quit smoking or reduce their harm.
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Introduction
The spread of e-cigarette use in many countries has brought front and center the debate
about their place in reducing the burden of tobacco-related disease (NASEM 2018). Two
questions arise. The first is what will be the net impact on smoking rates? Thus, if as is claimed,
(McNeill et al., 2018) that e-cigarettes might help adult smokers quit, is this counterbalanced by
youth initiation? (Warner & Mendez 2018) Recent findings from the National Youth Tobacco
Survey showing a 78% increase in e-cigarette use among US high school students in 2018 alone
(Cullen et al., 2018) have raised concerns about the growing number of tobacco naïve young
people taking up e-cigarettes in the US, as a cohort of nicotine-addicted young people may
subsequently transition to smoking (Aleyan et al., 2018; Soneji et al., 2017; Chapman et al.,
2018).
A second issue is whether e-cigarettes can contribute to tobacco harm reduction (THR).
This is based on the premise that adult smokers who cannot do without nicotine may be able to
reduce their risk by shifting from conventional cigarettes (Abrams et al., 2018). This assumes that
e-cigarettes are less harmful than conventional ones, a view that is widely accepted even if, in the
absence of long-term data, it is not possible to say how much (European Respiratory S 2018). It is
also contingent on individuals moving to exclusive e-cigarette smoking, as evidence shows that
those who use both are exposed to higher levels of some toxins than those who use either on their
own (Goniecwicz et al., 2018). From this perspective, advocating e-cigarettes to those suffering
from smoking-related diseases but who are unable to quit, such as patients with cardiovascular
disease (CVD), could be beneficial if it enables them to transition to sole e-cigarette use or, even
better, ultimately to abstain from both. Yet clinicians trying to help such individuals are currently
in uncharted territory without any definitive evidence to support their decision-making (Brandon
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et al., 2015; Drummond & Upson 2014). They also run the risk of exposing their patients to
additional risk either by advising the use of a potentially ineffective or even hazardous (Alzahrani
et al., 2018) cessation tool, or by withholding what could be a valuable means to help them
reduce their harm (NASEM 2018; CDC, Electronic cigarettes, 2018).
What is needed is research on the potential e-cigarettes might have to help adult smokers
reduce their harm in a real-world population setting, using appropriate study design and extended
follow up (Barrington-Trimis et al., 2015; Dutra & Glantz 2014).15,16 The 2018 report on ecigarettes by the National Academies of Science, Engineering, and Medicine (NASEM)
emphasized that because the e-cigarette phenomenon is relatively recent, “the majority of studies
… lack sufficient duration of follow-up to study the naturalistic cigarette smoking progression
sequence” (NASEM 2018).
In 2011, the NIH and FDA initiated the Population Assessment of Tobacco and Health
study (PATH), as the first population cohort to study tobacco use since Congress gave FDA the
authority to regulate tobacco products in 2009 (US Department of Health and Human Services,
2018; Hyland et al. 2017). Studies from PATH Waves 1 and 2 began answering some important
questions about e-cigarette transitions during the first year of follow up (Coleman et al., 2018;
Verplaetse et al., 2018). For example, Coleman and colleagues found that the majority of adult
dual users in Wave 1 (87·8%) either continued dual-use or relapsed to cigarette-only smoking at
one year follow up, compared to 12·1% who discontinued cigarette smoking (Coleman et al.,
2018). With the recent availability of Wave 3 data from PATH (October 2018), we have the
opportunity to look at an extended two-year follow-up of PATH’s data to examine a question that
is central to the THR debate; can e-cigarettes help adult smokers who are unable to quit reduce
their harm. This allows us to answer the key question facing clinicians faced with patients who
are heavy smokers.
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In a real-world setting, this question can be addressed by looking at adult dual ecigarette/cigarette users who are nicotine dependent, interested in quitting, and have a clinical
condition such as cardiovascular disease (CVD) that warrants their quitting, the transition to sole
e-cigarette use or total abstinence, versus relapse to exclusive smoking?
Methods
Study Sample
The PATH Study is a collaboration between the FDA and the National Institutes of
Health to inform the FDA’s regulatory approach to different tobacco products in the US (US
Department of Health and Human Services, 2018) PATH is an annual, nationally representative
longitudinal study of persons 12 years and older who are residents of households, and
noninstitutionalized civilians. Details have been described elsewhere (Hyland et al., 2017). The
response rate was 74·0% at Wave 1, yielding 32,320 participants, 83·2% at Wave 2, yielding
28,362 participants and 78·4% at Wave 3 yielding 28,148 participants. We examine tobacco use
among adults who reported current (past 30 days) dual-use of e-cigarette/cigarette at Wave 1
(2013-2014) and had follow-up information at Wave 3 (2015-2016). We examined three main
transitions (from Waves 1-3) among these dual users (cessation, harm-reduction, relapse), seeking
their associations with the following characteristics at Wave 1; 1) ND symptoms, 2) interest in
quitting, and 3) clinical CVD factors, in addition to baseline socioeconomic and behavioral
factors (Cohn et al., 2015; Loukas et al., 2016). The Institutional Review Board of Florida
International University reviewed the study and deemed it exempt.
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Study Measures
Assessment of tobacco use
The PATH Study enquires about several tobacco products including cigarettes, ecigarettes, cigars, cigarillos, little-filtered cigar, hookah, and smokeless tobacco. Since combined
e-cigarette/cigarette use is currently the most common and important e-cigarette use pattern from
a policy and regulatory standpoint, we defined current dual users as those who reported past 30
days (current) use of e-cigarettes and cigarettes in Wave 1, regardless of other tobacco products
used. We followed these dual users two years later, defining three main trajectories based on their
transitioning to; 1) no current use of any tobacco product (cessation transition); 2) current mono
e-cigarette use (harm reduction transition); or 3) current mono cigarette smoking (relapse
transition) at Wave 3.
Demographic and behavioral factors
Demographic variables included age, gender, sexual orientation, race/ethnicity,
education, income, employment status, and census region. Age, sexual orientation, race and
ethnicity, education, employment, census region, and BMI were categorized as shown in Table 1
(US Department of Health and Human Services, 2018; Cohn et al., 2015; Loukas et al., 2016).
Behavioral factors assessed in Wave 1 included age at first exposure to a tobacco
product, duration of tobacco product use, other tobacco use, marijuana use, and alcohol
consumption. Age at first exposure to tobacco products was categorized into <18, and ≥18 years.
Duration of tobacco use was derived by subtracting the age at first exposure to tobacco product
from participant’s age at Wave 1 and included as a continuous variable. Alcohol consumption and
marijuana use were assessed from the questions pertaining to past month drinking and marijuana
use categorized into “yes” and “no.”
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Nicotine dependence (ND) symptom
ND assessment was based on several questions asked at Wave 1 for each product reported
by participants. Since PATH did not include full scales for ND, but rather a selection of items
from different scales (Liu et al., 2017; DiFranza et al., 2002; Heatherton et al., 1991), we opted
for items that cover major domains of ND (e.g. craving, withdrawal, latency to smoke upon
awakening, smoking heaviness) (Baker et al., 2013), simple to use in our modeling, and have
been shown repeatedly to yield good measurement of ND (Baker et al., 2007). These were 1) time
to first [product] use after waking up?; 2) do you consider yourself addicted to [product]?; 3) do
you ever have strong cravings to smoke or use [product]?; 4) in the past 12 months, did you find
it difficult to keep from smoking or using [product] in places where it was prohibited?; 5) have
you ever felt like you really needed to use a [product]?; 6) did you cut down on activities that
were enjoyable or important to you because [product] was not permitted at activity?; and 7)
frequency of tobacco use among current dual users categorized into everyday (regular), vs. someday (not regular) use (US Department of Health and Human Services, 2018). All ND variables
were dichotomized into binary scoring as shown in Table 2 (US Department of Health and
Human Services, 2018). From these variables, we created a cumulative ND severity variable
based on the number of endorsements of the 7 ND items used (range 0-7).
Interest in quitting
We used two items from PATH to assess interest in quitting. The first was interest in
quitting (scale of 1-10; with 1, being not interested in quitting and 10, being extremely
interested). We categorized this variable into tertiles: 1-3, 4-7 and 8-10. The second was past year
quit attempts, measured as the “number of times tried to quit smoking/using tobacco product(s) in
the past 12 months.” This was categorized into 0 (no quit attempt), and ≥1 (one or more quit
attempts) (US Department of Health and Human Services, 2018).
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History of CVD-related illness
As our aim was to have an example of the potential effect of tobacco-associated clinical
conditions on e-cigarette related transitions, we picked reports of the history of CVD and related
conditions that are especially relevant to tobacco cessation and harm reduction. They were based
on self-reported positive response to the questions asking “Has a doctor, nurse or other health
professional ever told you that you have….” for diabetes mellitus (DM), heart attack (myocardial
infarction, MI), high blood pressure and high cholesterol (yes, no) (US Department of Health and
Human Services, 2018).
Statistical analyses
We calculated descriptive statistics for the main transitions of dual tobacco use between
Waves 1 and 3 (cessation, harm reduction, and relapse). An outcome variable was derived to
indicate respondents’ tobacco use transition at Wave 3 (0 = continued dual use, 1 = cessation (no
tobacco use), 2 = harm reduction (mono e-cigarette use), 3 = relapse (mono cigarette use). The
replicate weights provided by the PATH Study were used to obtain unbiased point and variance
estimates using Fay's Method of Balanced Repeated Replication, with the Fay coefficient value of
0·3, as recommended by the PATH Study team (US Department of Health and Human Services,
2018). Weighted percentages for sociodemographic and behavioral factors, ND symptoms,
interest in quitting, and history of clinical CVD factors at Wave 1, were reported by with their
corresponding 95% confidence intervals (CI) according to tobacco transitions at Wave 3. Pearson
chi-square tests for categorical variables and ANOVA for continuous variables were used to
evaluate differences among the tobacco use transitions and demographic and behavioral factors,
ND symptoms, interest in quitting and clinical CVD factors respectively (Tables 1,2 &3).
We applied logistic regression models to test the univariate associations between the
demographic, behavioral, ND, interest in quitting and clinical CVD factors at Wave 1 with the
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tobacco use transitions between Waves1-3. We reported unadjusted odds ratios (OR) with their
corresponding 95% CI for variables that had significant results only (Table 4). For the
multivariate predictors of main transitions among dual users (cessation, harm reduction, and
relapse), we fitted a multinomial regression model, adjusting for variables with inclusion p<0·2
from the univariate analysis or those that are theoretically important. Due to modest to moderate
correlation and collinearity between individual variables within each domain (e.g., ND) we
created the domain summary variables for ND symptoms, interest in quitting and clinical CVD
factors. These were categorized according to no endorsement of any ND, no interest in
quitting/quit attempt, or no history of CVD factor as “no,” and any endorsement of any of domain
components as “yes” for each domain (Tables 2,3).
Adjusted ORs with their corresponding 95% CIs were calculated and reported. Finally,
we tested the preplanned two-way interactions between the three domains of ND symptoms,
interest in quitting, and history of clinical CVD. Associations were considered statistically
significant at the alpha level of 0·05. Analyses were performed using SVY procedures in STATA
version 15·1 (StataCorp, College Station, TX).
Role of funding sources
Dr. Osibogun was supported by the Dissertation year fellowship from Florida
International University (FIU) and U54MD012393-01 for the FIU-RCMI during the time of
conducting this study. Drs. Bursac and Li are supported by U54MD012393-01 for the FIURCMI. Dr. Maziak is supported by NIH grants R01-DA035160, R01-TW010654, R01DA042477, and U54MD012393-01 for the FIU-RCMI. The funding sources had no role in the
study design, analysis or interpretation of the data, writing the manuscript, or the decision to
submit the paper for publication. No funding was received to support this manuscript.
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Results
Transitions of dual use at two year follow up
Table 1 shows the descriptive statistics of dual use transitions between Waves 1-3 of
PATH by main demographic and behavioral factors. Overall, 11·9% (95% CI 10·5–13·5) of dual
users followed the cessation transition (i.e., to no current use of any tobacco product), 7·0% (95%
CI 5·5–8·7) to the harm reduction transition (i.e., to mono e-cigarette use), 55·3% (95% CI 52·6–
58·0) were in the relapse transition (i.e., to mono cigarette use) and 25·8% (95% CI 23·5–28·3)
remained as dual users at two-year follow up.
Dual use transitions according to ND, interest in quitting, and clinical CVD factors
Overall, the majority of dual users reported at least one ND symptom (96·6%, 95% CI
95·7–97·4) and the most common symptom was addiction to tobacco (86·2%, 95% CI 84·0–
88·1) (Table 2). In terms of ND severity, 56·7% (95% CI 54·1-59·2) reported 4 to 5 ND
symptoms. Over half of participants (57·6%, 95% CI 54·6–60·6) had interest in quitting scores
of 8–10, and 83·2% (95% CI 80·5–85·7) reported one or more quit attempts in the past year.
Participants who reported at least one ND symptom were more likely to report relapse to cigarette
smoking (56·7%, 95% CI 53·7–59·7), while those who reported no ND symptoms were more
likely to report cessation (10·0%, 95% CI 8·7–11·6) at 2-year follow up (p<0·0001). Dual users
who reported an interest in quitting at Wave 1 were less likely to follow the cessation transition
(10·5%, 95% CI 8·7–12·5) at Wave 3 and more likely to remain as dual users (28·2%, 95% CI
25·4–31·1) (p=0.04). (Table 2)
Little over a third of participants (36%, 95% CI 33·1-39·0) overall reported a history of at
least one clinical CVD-related factor at Wave 1. The distributions of the clinical conditions across
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the tobacco use transitions were not statistically significant, but those who report at least one
condition were less likely to follow the cessation transition (9·1%, 95% CI 7·0–11·8) (Table 3).
Predictors of cessation, harm reduction, and relapse transitions
In the univariate regression analysis, among dual users at Wave 1, younger age (0·47,
95% CI 0·30–0·73), and longer duration of tobacco use (0·97, 95% CI 0·96–0·99) were
associated with decreased odds of cessation or harm reduction transitions at Wave 3 (p<0·05;
Table 4). Higher education (0·64, 95% CI 0·51–0·80) was associated with decreased odds of
relapse to cigarette smoking, while other tobacco use (1·63, 95% CI 1·16–2·28) and marijuana
use (1·71, 95% CI 1·13–2·57) were associated with increased odds of cessation transitions (Table
4).
The 3 main domains [ND symptoms (0·08, 95% CI 0·03–0·18), interest in quitting (0·26,
95% CI 0·10–0·70), and clinical conditions (0·61, 95% CI 0·41–0·89)], were associated with
decreased odds of cessation compared to continuing dual use (Table 4). Similarly, participants
who were in the higher categories of ND symptoms severity compared to 0–3 symptoms had a
decreased odds of cessation (4–5 symptoms: 0·26, 95% CI 0·15–0·39; and 6-7 symptoms: 0·20,
95% CI 0·12–0·35) and harm reduction transitions (4–5 symptoms: 0·51, 95% CI 0·32–0·81; and
6–7 symptoms: 0·26, 95% CI 0·12–0·55) (Table 4).
In the final adjusted multivariate model, those who reported the age of first exposure to
tobacco product of <18 years had a decreased odds of cessation transition (0·45, 95% CI 0·21–
0·97) compared to ≥18 years. Also, ND severity of 6–7 symptoms was associated with a
decreased odds of cessation (0·36, 95% CI 0·15–0·88) and harm reduction (0·18, 95% CI 0·04–
0·82) transitions compared to dual use (Table 5). Interest in quitting and clinical CVD factors
were not associated with either cessation or harm reduction transitions. The interactions between
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ND symptoms, interest in quitting and clinical CVD factors domains were not statistically
significant (all p>0·05).
Discussion
These findings are important because dual e-cigarette/cigarette use has become the most
common tobacco use pattern involving e-cigarettes in the US, with 55% of e-cigarette users also
smoking (Sung et al., 2018). We have three main findings, each helping to inform the debate on
the potential role of e-cigarettes in tobacco control.
The first is that among adult dual smokers, followed over 2 years in the PATH cohort
study, 18.9% followed either cessation (11·9%) or harm reduction (7%) transitions, compared to
55·3% relapsing to cigarette use, and 25·8% continuing dual use. In other words, the majority
relapsed and less than one in five transitioned to a less harmful situation. Second, individuals who
are highly addicted to nicotine were least likely either to quit or transition to a harm reduction
scenario with the use of e-cigarettes. Third, in the univariate analyses, those intending to quit or
who have a history of illnesses or conditions increasing their risk of cardiovascular disease were
less likely to cease smoking with e-cigarettes, and no more likely than others to transition to harm
reduction.
These findings are important because they challenge certain widely aired views. One is
that smokers taking up e-cigarettes are beginning a journey to reduced harm or even cessation
(Glantz & BAreham 2018). However, the available evidence has often been marred by
selectiveness of samples and outcomes, contradictory evidence, and mostly lacked length of
follow-up to answer this question (NASEM 2018; Weaver et al., 2018; Kalkhoran & Glantz
2016). There are, however, many accounts of individuals who claim benefit in using e-cigarettes
either to quit or reduce their harm by moving exclusively to e-cigarettes (Notley et al., 2018). Our
findings confirm that such individuals exist. However, a majority of dual users relapse to
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exclusive cigarette smoking, with a substantial minority remaining dual users. The latter is
especially important given concerns that the adverse health effects of continued dual use may be
greater than with either on their own (Wang et al., 2018).
Another is that e-cigarettes may be especially useful to those who are highly addicted to
nicotine, a group that includes many who have proven resilient to other interventions (Selya et al.,
2018). A third is that e-cigarettes may be most effective in those who intend to quit or who are
encouraged to do so because of other illnesses. We find no evidence either of these, with those
most addicted less likely to transition to reduced harm or cessation.
Our findings are consistent with the few earlier, although smaller studies, with the closest
in design an Italian study that included 223 dual users followed over 2 years found that 14.3%
followed the cessation transition, 12.5% the harm reduction transition, 16.6% continued dual use,
and 57.4% relapsed (Manzoli et al., 2016). Another study, from the US, included 151 dual users
among a larger sample of smokers, but while 43.7% were still dual users at two years, the other
data reported do not allow direct comparison with the present study (Zhuang et al., 2016).
These findings are of direct relevance to clinicians confronted with the dilemma of
whether or not to advise their tobacco smoking patients who need to quit but could not to try ecigarettes (Brandon et al., 2015). As noted, the notion that e-cigarettes can be the best option for
those who could not or will not quit otherwise has been central in the THR debate (Abrams et al.,
2018; Warner 2018). Yet even a dramatic event such as a history of MI was not associated with
increased success in using e-cigarettes to quit smoking or reduce harm by substituting cigarettes
with e-cigarettes. This is particularly relevant given the emerging evidence that concurrent ecigarette/cigarette use increases the risk of heart disease compared to each individually (Alzahrani
et al., 2018).
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Strengths and limitations
This study has some limitations. As the PATH did not include full scales for ND
measurement, we limited our assessment of ND to a subset of available questions (US
Department of Health and Human Services, 2018).
Previous research has demonstrated that individual items, several included here (e.g.,
time of first tobacco product; frequency of use), yield comparable measurements to the full scales
(Baker et al., 2007). Second, although this analysis provides useful information on the transition
from dual use over two time-points, we did not analyze participants’ behaviors between waves.
However, our main aim was to track real-world evolution of dual use over an extended period
rather than the dynamics of changes occurring during this period or factors influencing them.
Third, tobacco use, interest in quitting and history of CVD were based on self-reports. Previous
research, however, shows a good correlation between self-report of tobacco use and biomarkers
of tobacco exposure, or clinical CVD and medical records (Yuji et al., 2004). Interest in quitting,
moreover, was correlated with past year quit attempts (r= 0.20; p<0.0001). Finally, since this is a
population-based study rather than a cessation trial, it was not possible to apply a definition of
cessation based on prolonged abstinence as is used in intervention studies. Using such a
definition would have led to even fewer people classified as the cessation or harm reduction
transitions. Thus, if anything, our findings exaggerate the probability of cessation. Nevertheless,
the major strengths of this study include a representative sample of US adults, longitudinal design
and length of follow up, and detailed history of different tobacco products.
Conclusions
The present study shows that four out of five dual users continue as dual users and
cigarette users two years later. Nicotine dependence (ND) severity and early age (<18 years) of
first exposure to tobacco were associated with less odds of following a cessation transition at 2-
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year follow up, while interest in quitting, and history of illness were not associated with favorable
transitions towards cessation or harm reduction.
Given all the uncertainty about e-cigarette and dual use short- and long-term health
effects, our real-world population results cast serious doubt about a central paradigm of THR
based on e-cigarettes’ potential to help adult smokers who cannot quit otherwise. It seems that,
with or without e-cigarettes, cessation and harm reduction success are very challenging in this
population.
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Tables and figures

Table 1 – Prevalence characteristics of adult (≥18 years) dual e-cigarette/cigarette users according to main transitions at 2-year
follow-up:
PATH Study, 2013-2016
Wave 3
Overall
Cessation
Harm
Relapse
Dual use
p value
Wave 1
%, (95% CI)
%, (95% CI)
reduction
%, (95% CI)
%, (95% CI)
%, (95% CI)
Total (n=1870)
100·0
11·9 (10·5-13·5)
7·0 (5·5-8·7)
55·3 (52·6-58·0) 25·8 (23·5-28·3)
Demographic factors
Age, years (n=1870)
0·0002
18-24
17·4 (15·7-19·2) 20·2 (16·1-25·1)
7·2 (4·8-10·6)
49·6 (43·9-55·4) 23·0 (18·8-27·8)
25-34
26·3 (23·9-29·0) 12·7 (9·7-16·5)
7·1 (4·8-10·4)
52·6 (47·5-57·7) 27·6 (23·1-32·6)
≥35
56·3 (53·1-59·5)
9·0 (7·4-10·9)
6·8 (4·9-9·2)
58·4 (54·7-62·0) 25·9 (23·1-28·9)
Gender (n=1870)
0·15
Male
45·7 (43·1-48·3) 13·6 (11·3-16·2)
7.5 (5·6-10·0)
53·4 (49·9-56·9) 25·5 (22·3-29·0)
Female
54·3 (51·7-56·9) 10·5 (8·8-12·6)
6·4 (4·9-8·4)
57·0 (53·4-60·5) 26·1 (23·2-29·2)
Sexual orientation
0·25
(n=1839)
Heterosexual
91·1 (89·6-92·4) 11·9 (10·4-13·6)
6·7 (5·2-8·5)
56.0 (53·2-58·7) 25·4 (22·9-28·2)
Lesbian/gay/bisexual/other
8·9 (7·6-10·4)
8·7 (5·4-13·8)
8·2 (4·7-14·0)
52·3 (45·0-59·5) 30·8 (24·8-37·6)
Race/Ethnicitya (n=1851)
0·004
Non-Hispanic white
74·8 (72·4-76·9)
9·9 (8·5-11·5)
7·2 (5·5-9·3)
55·3 (52·2-58·4) 27·6 (24·8-30·5)
Non-Hispanic black
8·2 (7·0-9·6)
14·7 (9·6-21·9)
6·4 (2·8-14·0)
60·9 (51·4-69·7) 18·0 (11·5-26·9)
Hispanic
11·6 (10·1-13·3) 21·7 (15·6-29·4)
5·4 (3·2-9·0)
50·7 (43·3-58·0) 22·2 (17·6-27·6)
Other
5·4 (4·4-6·7)
14·2 (7·9-24·2)
6·5 (2·9-13·9)
51·9 (40·7-62·9) 27·5 (18·0-39·6)
b
Education (n=1870)
0·0012
≤High school
48·4 (45·8-51·0) 10·2 (8·4-12·4)
6·3 (4·3-9·1)
60·9 (57·1-64·6) 22·5 (19·7-25·7)
≥Some college degree
51·6 (49·0-54·2) 13·5 (11·3-16·1)
7·5 (5·7-9·8)
50·1 (46·5-53·7) 28·9 (25·8-32·3)
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Household income
(n=1737)
<$25,000
47·3 (44·4-50·2)
$25,000 to $74,999
38·1 (35·5-40·8)
≥$75,000
14·6 (12·6-17·0)
Employment status
(n=1864)
Full-time
44·9 (42·1-47·7)
Part-time
18·0 (16·0-20·1)
Don’t currently work for
37·2 (34·1-40·3)
pay
BMI, kg/m2(n=1823)
<30·0
70·3 (68·0-72·4)
≥30·0
29·8 (27·6-32·0)
US Census region
(n=1870)
Northeast
13·9 (12·0-15·9)
Midwest
25·4 (23·2-27·7)
South
39·9 (37·1-42·8)
West
20·8 (18·2-23·7)
Behavioral factors
Age at 1st exposure to tobacco product (y)
(n=1870)
<18
76·5 (74·4-78·4)
≥18
23·5 (21·6-25·6)
Duration of tobacco use
(n=1870)
Mean (SD)
22·2 (14·6)
Other tobacco use
(n=1870)
Yes
25·6 (23·0-28·4)
No
74·4 (71·6-77·0)

0·003
11·2 (9·0-13·8)
10·5 (8·5-12·9)
17·8 (13·1-23·6)

5·3 (3·6-7·7)
8·1 (5·9-10·9)
9·4 (5·2-16·5)

57·4 (53·6-61·2)
56·6 (52·0-61·0)
46·2 (38·5-54·1)

26·2 (23·0-29·5)
24·8 (20·7-29·4)
26·6 (20·8-33·4)
0·22

12·3 (10·1-14·9)
14·2 (10·6-18·8)
10·4 (8·2-13·0)

6·8 (5·1-9·1)
9·2 (6·2-13·4)
6·0 (4·2-8·5)

56·6 (52·7-60·4)
51·5 (45·7-57·3)
56·0 (52·1-59·9)

24·3 (20·8-28·1)
25·1 (21·0-29·8)
27·6 (24·5-30·9)
0·31

12·6 (10·7-14·7)
9·5 (7·1-12·7)

7·0 (5·4-9·1)
7·2 (5·0-10·3)

54.1 (51·2-57·0)
58·2 (53·1-63·1)

26·3 (23·7-29·0)
25·0 (20·7-30·0)
0·45

15·0 (11·0-20·0)
10·1 (8·3-12·3)
11·6 (9·2-14·4)
12·8 (9·6-16·8)

6·4 (3·6-11·3)
5·5 (3·3-8·9)
6·8 (4·6-10·1)
9·2 (6·5-12·8)

56·7 (50·7-62·5)
58·2 (54·1-62·1)
54·6 (49·1-60·0)
52·5 (47·3-57·6)

21·9 (16·9-28·0)
26·3 (22·4-30·6)
27·0 (22·7-31·8)
25·6 (20·7-31·2)
0·0012

10·1 (8·4-12·0)
17·9 (14·3-22·2)

6·5 (5·1-8·3)
8·1 (5·5-12·0)

56·5 (53·3-59·6)
31·6 (46·3-56·8)

26·9 (24·1-29·9)
22·4 (18·1-27·4)
0·0005

16·8 (14·8)

22·1(15·7)

23·0 (14·1)

23·0 (14·7)
0·005

16·6 (13·5-20·2)
10·3 (8·9-12·0)

6·6 (4·5-9·5)
7·0 (5·4-9·1)
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51·4 (46·9-55·9)
56·7 (53·5-59·8)

25·5 (21·6-29·9)
25·9 (23·3-28·8)

Alcohol use within 30
daysc (n=1616)
Yes
No
Marijuanad (n=1245)
Yes
No

0·19
67·0 (63·5-70·4)
33·0 (29·6-36·5)

12·5 (10·5-14·9)
9·8 (7·3-13·0)

7·1 (5·4-9·2)
6·4 (4·2-9·5)

55·3 (51·8-58·7)
54·1 (49·4-58·8)

25·2 (22·2-28·4)
29·7 (25·5-34·3)

31·5 (28·5-34·5)
68·5 (65·5-71·5)

15.3 (12·0-19·2)
10·4 (8·4-13·0)

6·5 (4·4-9·5)
6·8 (4·9-9·2)

53·5 (48·4-58·5)
53·9 (49·9-57·8)

24·8 (20·1-30·0)
29·0 (25·4-32·8)

0·09

Definitions: Cessation indicates no current tobacco use, harm reduction: e-cigarette mono use, relapse: cigarette mono use. Abbreviation: PATH
indicates Population Assessment of Tobacco and Health; CI, confidence intervals; US, United States, BMI, body mass index; SD, standard deviation.
a
Other refers to Non-Hispanic American Indian or Alaska Native, Non-Hispanic Asian/Native Hawaiian or Other Pacific Islander and persons with
multiple races. b≤ high school denotes less than high school/GED/high school graduate; ≥some college degree denotes some
college/associate’s/bachelor’s/advanced degree. cAnswered by respondents who have ever used alcohol and used alcohol in the past 30 days. dAnswered
by respondents who used marijuana in past 30days. Percentages are rounded up to 1 decimal place.

85

Table 2 – Nicotine dependence symptoms and interest in quitting among adult (≥18 years) dual e-cigarette/cigarette users
according to main transitions at 2-year follow-up: PATH Study, 2013-2016
Tobacco use at 2-year follow-up (Wave 3)
Wave 3
Overall,
Cessation,
Harm reduction,
Relapse,
Dual use,
p value
Wave 1
%, (95% CI)
%, (95% CI)
%, (95% CI)
%, (95% CI)
%, (95% CI)
Soon after waking, minutes (n=1621)
0·55
<30
83·2 (81·0-85·2)
9·0 (7·5-10·8)
6·4 (4·8-8·4)
58·1 (54·5-61·5)
26·5 (23.6-29·7)
≥30
16·8 (14·8-19·0)
8·6 (5·2-13·7)
8·6 (5·7-12·8)
54·0 (46·8-61·1) 28·8 (23·2-35·1)
Addicted to tobacco (n=1793)
<0·0001
Yes
86·2 (84.0-88.1)
8·9 (7·5-10·4)
6·4 (5·0-8·2)
58·0 (54·8-61·1) 26·8 (24·0-29·6)
No
13·9 (11.9-16.0) 26·9 (21·5-33·1) 10·1 (6·6-15·0)
42·2 (35·7-49·0) 20·9 (15·6-27·3)
Strong craving for tobacco product (n=1795)
<0·0001
Yes
82·4 (80·4-84·2)
8·4 (7·0-10·1)
6·2 (4·9-8·0)
57·9 (54·4-61·4) 27·4 (24·6-30·5)
No
17·6 (15·8-19·6) 25·1 (20·3-30·7) 10·3 (6·8-15·3)
45·9 (40·0-52·0) 18·7 (14·6-23·7)
Felt the need to use tobacco (n=1794)
<0·0001
Yes
85·6 (83·7-87·4)
8·9 (7·5-10·5)
6·9 (5·3-8·5)
57·6 (54·4-60·8) 26·8 (24·0-29·8)
No
14·4 (12·6-16·3) 26·0 (20·7-32·0)
8·4 (5·3-13·1)
45·1 (37·9-52·4) 20·5 (15·9-26·1)
Use tobacco in prohibited places (n=1795)
0·03
Yes
28·0 (25·8-30·2)
7·7 (5·9-9·9)
6·3 (4·2-9·5)
59·7 (54·7-64·5) 26·3 (22·2-30·7)
No
72·1 (69·8-74·2) 12·8 (11·1-14·7)
7·2 (5·5-9·4)
54·3 (51·0-57·6) 25·8 (23·0-28·7)
Gave up activities (n=1794)
0·97
Yes
14·3 (12·7-16·0) 10·6 (7·4-14·9)
6·6 (3·6-11·6)
56·5 (49·6-63·5) 26·4 (20·5-33·2)
No
85·7 (84·0-87·3) 11·5 (9·9-13·2)
7·0 (5·5-8·9)
55·7 (52·6-58·8) 25·8 (23·2-28·6)
Frequency of tobacco use (n=1631)
<0.0001
Regular
64·4 (61·7-67·1) 14·9 (12·1-18·1)
9·9 (7·4-13·1)
64·0 (60·5-67·4) 25·0 (22·0-28·3)
Not regular
35·6 (32·9-38·4)
6·0 (4·7-7·7)
5·0 (3·5-6·9)
45·1 (40·9-49·3) 30·2 (26·4-34·3)
ND symptoms severity categories (n=1796)
<0.0001
0-3
23·4 (21·0-25·9) 24·4 (19·8-29·6) 10·5 (7·4-14·6)
44·0 (38·4-49·7) 21·2 (17·3-25·8)
4-5
56·7 (54·1-59·2)
7·9 (6·2-9·8)
6·9 (5·2-9·2)
57·3 (53·6-61·0) 27·9 (24·7-31·3)
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6-7
20·0 (18·1-22·1)
ND symptoms domain (n=1796)
Yes
96·6 (95·7-97·4)
No
3·4 (2·6-4·3)
Interest in quitting scale (n=1280)
1-3
12·0 (10·1-14·1)
4-7
30·4 (27·8-33·2)
8-10
57·6 (54·6-60·6)
Quit attempt (n=1007)
≥1 (Yes)
83·2 (80·5-85·7)
0 (No)
16·8 (14·3-19·5)
Interest in quitting
domain (n=1330)
Yes
95·5 (94·2-96·5)
No
4·5 (3·5-5·8)

6·0 (4·1-8·7)

3·3 (1·8-5·8)

65·0 (58·7-70·8)

25·7 (20·8-31·3)

10·0 (8·7-11·6)
48·9 (35·3-62·7)

6·8 (5·4-8·6)
13·8 (7·2-24·8)

56·7 (53·7-59·7)
27·2 (16·8-40·8)

26·4 (23·9-29·1)
10·1 (5·0-19·5)

10·4 (6·3-16·7)
12·0 (9·0-15·7)
9·6 (7·4-12·4)

4·7 (2·2-10·0)
6·0 (3·6-9·7)
7·5 (5·4-10·3)

59·7 (51·6-67·4)
53·8 (48·0-59·6)
54·3 (50·3-58·3)

25.2 (18·6-33·1)
28.2 (23·2-33·8)
28·6 (25·4-32·0)

10·8 (8·8-13·2)
12·1 (7·4-19·2)

7·8 (5·9-10·2)
6·2 (3·1-12·0)

52·6 (48·7-56·5)
60·0( 50·2-69·1)

28·8 (25·6-32·2)
21·6 (14·8-30·5)

<0.0001

0.68

0·31

0.04
10·5 (8·7-12·5)
23·1 (13·2-37·4)

6·9 (5·3-8·6)
6·8 (2·0-20·5)

54·5 (51·3-57·7)
54·0 (40·0-67·4)

28·2 (25·4-31·1)
16·0 (8·2-29·0)

Definitions: Cessation indicates no current tobacco use, harm reduction: e-cigarette mono use, relapse: cigarette mono use. Abbreviation: PATH
indicates Population Assessment of Tobacco and Health; CI, confidence interval, ND, nicotine dependence. Percentages are rounded up to 1 decimal
place.
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Table 3 – Clinical CVD factors among adult (≥18 years) dual e-cigarette/cigarette users by main transitions at 2-year followup: PATH Study, 2013-2016
Tobacco use at 2-year follow-up (Wave 3)
Wave 3
Overall,
Cessation,
Harm reduction,
Relapse,
Dual use,
p value
Wave 1
%, (95% CI)
%, (95% CI)
%, (95% CI)
%, (95% CI)
%, (95% CI)
Diabetes (n=1865)
0·87
Yes
11·1 (9·5-12·9)
10·9 (7·0-16·5)
8·3 (4·7-14·3)
54·9 (47·7-62·0) 26·0 (19·9-33·1)
No
89·0 (87·1-90·5) 12·1 (10·5-13·9)
6·8 (5·2-8·6)
55·3 (52·5-58·1) 25·8 (23·4-28·4)
High cholesterol (n=1865)
0·19
Yes
18·5 (16·6-20·6) 10·6 (7·4-14·8)
8·6 (5·3-13·5)
51·1 (44·6-57·5) 29·8 (24·6-35·6)
No
81·5 (79·4-83·4) 12·2 (10·6-14·1)
6·5 (5·1-8·2)
56·3 (53·4-59·1) 25·0 (22·6-27·6)
Hypertension (n=1865)
0·003
Yes
23·4 (20·9-26·0)
8·4 (5·9-11·7)
5·4 (3·3-8·9)
63·8 (59·3-68·0) 22·5 (18·6-26·9)
No
76·6 (74·0-79·1) 13·0 (11·3-14·8)
7·3 (5·7-9·3)
52·8 (49·6-55·9) 27·0 (24·2-29·9)
Myocardial infarction (n=1865)
0·84
Yes
3·3 (2·5-4·3)
8·1 (2·8-21·4)
5·8 (1·6-18·8)
57·3 (43·2-70·3) 28·8 (17·7-43·3)
No
96·7 (95·7-97·5) 12·0 (10·5-13·7)
6·9 (5·5-8·7)
55·3 (52·5-58·0) 25·8 (23·4-28·4)
Clinical factors domain (n=1869)
0.08
Yes
36·0 (33·1-39·0)
9·1 (7·0-11·8)
6·8 (4·7-9·7)
54·7 (51·2-58·2) 24·8 (22·1-27·7)
No
64·0 (61·1-66·9) 13·5 (11·6-15·6)
7·0 (5·4-9·7)
56·4 (52·1-60·6) 27·7 (23·8-31·9)
Definitions: Cessation indicates no current tobacco use, harm reduction: e-cigarette mono use, relapse: cigarette mono use. Abbreviation: PATH
indicates Population Assessment of Tobacco and Health; CI, confidence interval. Percentages are rounded up to 1 decimal place.
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Table 4 – Univariate predictors of dual use transitions at 2-year follow-up among US adults (≥18 years):
PATH study, 2013-2016
Cessation
Harm reduction
Relapse
Unadjusted OR (95% CI)
Unadjusted OR (95%
Unadjusted OR
CI)
(95% CI)
Demographic and behavioral factors
Age, years (ref: 18–24)
25–34
0·52 (0·32-0·85)
0·82 (0·47-1·43)
0·88 (0·61-1·27)
≥ 35
0·40 (0·26-0·61)
0·84 (0·49-1·43)
1·05 (0·76-1·44)
Educationa
≥Some college degree (vs. ≤high school)
1·03 (0·75-1·41)
0·92 (0·55-1·54)
0·64 (0·51-0·80)
US census region (ref: Northeast)
Midwest
0·56 (0·33-0·96)
0·71 (0·28-1·76)
0·86 (0·58-1.26)
South
0·63 (0·36-1·08)
0·86 (0·36-2·05)
0·78 (0·52-1·18)
West
0·73 (0·41-1·31)
1·22 (0·51-2·93)
0·80 (0·52-1·21)
st
Age at 1 exposure to tobacco product, years
<18 (vs. ≥18)
0·47 (0·30-0·73)
0·67 (0·39-1·13)
0·91 (0·66-1·26)
Duration of tobacco use
0·97 (0·96-0·99)
1·00 (0·98-1·01)
1·00 (0·99-1·01)
Other tobacco use
Yes (vs. no)
1·63 (1·16-2·28)
0·95 (0·59-1·53)
0·92 (0·71-1·20)
Marijuana
Yes (vs. no)
1·71 (1·13-2·57)
1·13 (0·63-2·03)
1·16 (0·83-1·62)
ND symptoms
Addicted to tobacco
Yes (vs. no)
0·26 (0·16-0·41)
0·49 (0·28-0·87)
1·07 (0·72-1·60)
Strong cravings for tobacco
Yes (vs. no)
0·23 (0·15-0·36)
0·41 (0·26-0·67)
0·86 (0·59-1·25)
Felt the need to use tobacco
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Yes (vs. no)
Use tobacco in prohibited places
Yes (vs. no)
Frequency of tobacco use
Regular (vs. not regular)
ND symptoms severity (ref: 0-3)
4-5
6-7
ND symptoms domain
Presence of ND symptoms
Yes (vs. no)
Interest in quitting domain
Presence of interest in quitting
Yes (vs. no)
Clinical factors domain
Presence of clinical factors
Yes (vs. no)

0·26 (0·17-0·41)

0·61 (0·36-1·01)

0·98 (0·66-1·46)

0·59 (0·42-0·84)

0·87 (0·50-1·51)

1·08 (0·84-1·39)

0·21 (0·13-0·31)

0·55 (0·32-0·96)

0·96 (0·64-1·44)

0·26 (0·15-0·39)
0·20 (0·12-0·35)

0·51 (0·32-0·81)
0·26 (0·12-0·55)

0·99 (0·72-1·38)
1·22 (0·81-1·84)

0·08 (0·03-0·18)

0·19 (0·07-0·51)

0·80 (0·32-1·99)

0·26 (0·10-0·70)

0·57 (0·10-3·39)

0·57 (0·25-1·34)

0·61 (0·41-0·89)

0·88 (0·56-1·38)

0·92 (0·71-1·19)

Definitions: Cessation indicates no current tobacco use, harm reduction: e-cigarette mono use, relapse: cigarette mono use. Abbreviation: PATH
indicates Population Assessment of Tobacco and Health, OR, odds ratio, CI, confidence interval. Multinomial logistic regression modelling with
dual use as reference group, unadjusted odds ratio for variables that had significant results (p<0.05). a ≤ high school denotes less than high
school/GED/high school graduate; ≥some college degree denotes some college/associate’s/bachelor’s/advanced degree. Bold numbers indicate
statistical significance (p<0.05)

90

Table 5 – Multivariate predictors of dual use transitions at 2-year follow up among US adults (≥18 years):
PATH study, 2013-2016
Cessation
Harm reduction
Relapse
Predictors
Adjusted OR (95% CI)
Adjusted OR (95% CI)
Adjusted OR
(95% CI)
Demographic and behavioral factors
Age at 1st exposure to tobacco, years
<18 (vs. ≥18)
0·45 (0·21-0·97)
0·51 (0·16-1·66)
0·77 (0·42-1·40)
ND symptoms
ND symptoms severity (ref: 0-3)
4-5
0·41 (0·21-0·85)
0·48 (0·20-1·17)
0·90 (0·58-1·42)
6-7
0·36 (0·15-0·88)
0·18 (0·04-0·82)
1·06 (0·61-1·85)
Definitions: Cessation indicates no current tobacco use, harm reduction: e-cigarette mono use, relapse: cigarette mono use. Abbreviation: PATH
indicates Population Assessment of Tobacco and Health, OR, odds ratio, CI, confidence interval. Multinomial logistic regression modelling with
dual use as reference group. Only significant results (p<0·05) are reported. Due to high correlation between ND severity and ND symptoms
summary variables (r=0.8, p<0.0001), we introduced them separately in the multivariate model. Bold numbers indicate statistical significance
(p<0·05)
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Conclusions
This dissertation sought to investigate poly-tobacco use in the US given the ever-evolving
tobacco landscape with numerous tobacco products that appeal socially to youth and are
perceived to be generally less harmful than traditional cigarettes. We estimated the prevalence of
poly-tobacco use among youth (12-17 years) and young adults (18-34 years) and also identified
correlates of poly-tobacco use in this sub-population of tobacco users. Our findings indicated that
approximately 4% of youth and 18% of young adults are poly-tobacco users in the general
population, with the prevalence much higher among tobacco users. The most common polytobacco combination in both age-groups were cigarettes and e-cigarettes. Additionally, we
identified youth heavy drinkers had higher odds of poly-tobacco use compared to mono-tobacco
use. Among young adults, males, younger adults (18-24 years), those with lower levels of
educational attainment, those residing in the South, heavy drinkers, and marijuana users had
statistically significant higher odds of poly-tobacco use compared to mono-tobacco use.
We showed in our second study that young and adult current e-cigarette users, had more
relapse, dual-use, and transition to cigarette smoking. Furthermore, there was e-cigarette uptake
among young never cigarette smokers than quitting among adult smokers. These findings suggest
that e-cigarette use has the possibility of increasing the nicotine addiction base among youth.
Finally, the last study showed that among US adults, four out of five dual (e-cigarette and
cigarette) users continue as dual users and cigarette users two years later. Nicotine dependence
(ND) severity and early age (<18 years) of first exposure to tobacco were associated with lower
odds of following a cessation transition at 2-year follow up, while interest in quitting, and history
of illness were not associated with favorable transitions towards cessation or harm reduction.
Findings suggestive of the fact that regardless of e-cigarette use, dual users are a challenging
group when it comes to quitting cigarettes.
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Collectively, our findings from the three waves of the PATH about tobacco use evolution
among US youth and adults offers a cause for concern for the balance between the beneficial and
harmful potentials of e-cigarette use in the general population. Our study findings emphasize the
need for stricter tobacco regulatory policies, so as to prevent another tobacco epidemic among
young people.
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